8050001	1	2005	15922309	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	27
8050001	2	2005	15922309	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	27
8050001	3	2005	15922309	Neither	Gray Matter	Disease Effects	Bipolar Disorder	32
8050002	1	2007	17027928	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	33
8050002	2	2007	17027928	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	33
8050003	1	2006	16791083	Neither	Gray Matter	Age Effects	Normals	26
8050004	1	2002	12202269	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
8050004	2	2002	12202269	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	20
8050005	1	2004	15489397	Increases in Patients	Gray Matter	Disease Effects	Myotonic Dystrophy, Normals	22
8050006	1	2006	17093899	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	10
8050006	2	2006	17093899	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	10
8050007	1	2001	11467904	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	16
8050007	2	2001	11467904	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	16
8050007	3	2001	11467904	Increases in Controls	Gray Matter	Disease Effects, Age Effects	Alzheimer's Disease, Normals	16
8050007	4	2001	11467904	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	16
8050009	1	2006	17040475	Neither	Gray Matter	Normal Mapping	Normals	50
8050010	1	2006	16979909	Neither	Gray Matter	Normal Mapping	Normals	63
8050011	1	2006	16914835	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
8050011	2	2006	16914835	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	15
8050012	1	2007	17407506	Increases in Controls	Gray Matter	Normal Mapping, Disease Effects	Normals	20
8050012	2	2007	17407506	Neither	Gray Matter	Normal Mapping, Disease Effects	Normals	20
8050013	1	2004	15488421	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	45
8050013	2	2004	15488421	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	40
8050013	3	2004	15488421	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	45
8050013	4	2004	15488421	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	40
8050014	1	2008	17497629	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease	9
8050015	1	2006	16702001	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	44
8050015	2	2006	16702001	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	24
8050015	3	2006	16702001	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	24
8050016	1	2007	17028119	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Parkinson's Disease	8
8050016	2	2007	17028119	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	16
8050016	3	2007	17028119	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Parkinson's Disease	8
8050017	1	2006	16837880	Increases in Patients	Gray Matter	Drug Effects	Postmenopause	7
8050017	2	2006	16837880	Neither	Gray Matter	Drug Effects	Postmenopause	7
8050019	1	2004	15036621	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease	7
8050019	2	2004	15036621	Increases in Controls	Gray Matter	Disease Effects	Dementia	2
8050020	1	2004	15006669	Increases in Controls	Gray Matter	Disease Effects	Normals, Smith Magenis Syndrome	5
8050020	2	2004	15006669	Increases in Controls	Gray Matter	Disease Effects	Idiopathic Mental Retardation, Smith Magenis Syndrome	5
8050021	1	2004	15364683	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	21
8050021	2	2004	15364683	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	22
8050023	1	2003	12873851	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	11
8050023	2	2003	12873851	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	11
8050023	3	2003	12873851	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Semantic Dementia	11
8050023	4	2003	12873851	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Semantic Dementia	11
8050024	1	2004	15326259	Increases in Controls	Gray Matter	Disease Effects	Dyslexia, Normals	10
8050025	1	2004	14742598	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	12
8050025	2	2004	14742598	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	12
8050026	1	2007	17334661	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	14
8050027	1	2003	14534916	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	12
8050027	2	2003	14534916	Neither	Gray Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	12
8050027	3	2003	14534916	Increases in Controls	White Matter	Disease Effects	Multiple-System Atrophy, Normals	12
8050027	4	2003	14534916	Neither	White Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	12
8050028	1	2006	16161039	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050028	2	2006	16161039	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals, Spinocerebellar Ataxia	9
8050029	1	2003	14534423	Increases in Controls	Gray Matter	Disease Effects	Ataxia, Normals	9
8050030	1	2004	15257132	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	10
8050030	2	2004	15257132	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	10
8050031	1	2005	15994127	Increases in Controls	Gray Matter	Disease Effects	Narcolepsy, Normals	12
8050032	1	2007	16469419	Neither	Gray Matter	Age Effects	Normals	29
8050032	2	2007	16469419	Neither	White Matter	Age Effects	Normals	29
8050033	1	2001	11274316	Increases in Controls	Gray Matter	Disease Effects	Dyslexia, Normals	14
8050034	1	2004	15469950	Increases in Controls	White Matter	Disease Effects	Bipolar Disorder, Normals	35
8050035	1	2006	16469198	Neither	White Matter	Disease Effects	Bipolar Disorder	11
8050037	1	2006	16108017	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	15
8050038	1	2006	16499767	Increases in Controls	Gray Matter	Disease Effects	Childhood Absence Epilepsy, Normals	13
8050038	2	2006	16499767	Increases in Patients	Gray Matter	Disease Effects	Childhood Absence Epilepsy, Normals	13
8050038	3	2006	16499767	Increases in Patients	White Matter	Disease Effects	Childhood Absence Epilepsy, Normals	13
8050038	4	2006	16499767	Increases in Patients	White Matter	Disease Effects	Childhood Absence Epilepsy, Normals	13
8050039	1	2007	17047671	Increases in Controls	Gray Matter	Drug Effects, Disease Effects	Alcoholism, Normals	28
8050039	2	2007	17047671	Increases in Controls	White Matter	Drug Effects, Disease Effects	Alcoholism, Normals	28
8050040	1	2007	17464719	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	2	2007	17464719	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	3	2007	17464719	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	4	2007	17464719	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	5	2007	17464719	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	6	2007	17464719	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	7	2007	17464719	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	8	2007	17464719	Increases in Controls	Gray Matter	Drug Effects, Disease Effects, Treatment Effects	Bipolar Disorder, Normals	24
8050040	9	2007	17464719	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	10	2007	17464719	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
8050040	11	2007	17464719	Neither	Gray Matter	Disease Effects	Bipolar Disorder	24
8050040	12	2007	17464719	Neither	Gray Matter	Disease Effects	Bipolar Disorder	24
8050040	13	2007	17464719	Neither	Gray Matter	Treatment Effects, Drug Effects	Bipolar Disorder	24
8050040	14	2007	17464719	Neither	Gray Matter	Disease Effects	Bipolar Disorder	24
8050040	15	2007	17464719	Neither	Gray Matter	Disease Effects	Bipolar Disorder	24
8050041	1	2007	17499524	Neither	Gray Matter	Gender Effects	Normals	184
8050041	2	2007	17499524	Neither	Gray Matter	Gender Effects	Normals	184
8050042	1	2006	16371250	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	12
8050042	2	2006	16371250	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	12
8050043	1	2002	12395096	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	22
8050043	2	2002	12395096	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	16
8050044	1	2005	16038682	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	14
8050045	1	2005	15843423	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	21
8050045	2	2005	15843423	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	21
8050045	3	2005	15843423	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	17
8050046	1	2003	12725766	Increases in Controls	Gray Matter	Disease Effects	Normals, Pure Autonomic Failure	15
8050047	1	2005	15702141	Increases in Patients	Gray Matter	Drug Effects, Treatment Effects	Nonschizophrenia Psychosis	20
8050047	2	2005	15702141	Increases in Controls	Gray Matter	Drug Effects, Treatment Effects	Nonschizophrenia Psychosis	20
8050047	3	2005	15702141	Increases in Patients	Gray Matter	Drug Effects, Treatment Effects	Nonschizophrenia Psychosis	20
8050047	4	2005	15702141	Neither	Gray Matter	Drug Effects, Treatment Effects	Nonschizophrenia Psychosis	30
8050048	1	2005	15997014	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	20
8050050	1	2006	16763039	Neither	Gray Matter	Learning	Normals	12
8050050	2	2006	16763039	Neither	Gray Matter	Learning	Normals	12
8050051	1	2006	16520065	Increases in Controls	Gray Matter	Disease Effects	Limb Amputation, Normals	28
8050051	2	2006	16520065	Increases in Controls	Gray Matter	Disease Effects	Limb Amputation, Normals	28
8050051	3	2006	16520065	Increases in Controls	Gray Matter	Disease Effects	Limb Amputation, Normals	28
8050051	4	2006	16520065	Increases in Controls	Gray Matter	Disease Effects	Limb Amputation, Normals	28
8050052	1	2003	14610125	Increases in Controls	Gray Matter	Disease Effects	Dystonia, Normals	10
8050052	2	2003	14610125	Increases in Controls	Gray Matter	Disease Effects	Dystonia, Normals	10
8050053	1	2005	15965207	Increases in Controls	Gray Matter	Disease Effects	Normals, Traumatic Head Injury	9
8050053	2	2005	15965207	Increases in Controls	Gray Matter	Disease Effects	Traumatic Head Injury	9
8050053	3	2005	15965207	Increases in Controls	Gray Matter	Disease Effects	Traumatic Head Injury	9
8050054	1	2004	15122716	Increases in Patients	Gray Matter	Disease Effects	Dystonia, Normals	36
8050055	1	2007	17882035	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	9
8050055	2	2007	17882035	Increases in Controls	White Matter	Disease Effects	Huntington's Disease, Normals	9
8050056	1	2003	14697007	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	12
8050056	2	2003	14697007	Increases in Patients	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	12
8050056	3	2003	14697007	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	12
8050056	4	2003	14697007	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	29
8050057	1	2007	16603709	Neither	White Matter	Learning, Normal Mapping	Normals	10
8050057	2	2007	16603709	Neither	White Matter	Learning, Normal Mapping	Normals	10
8050057	3	2007	16603709	Neither	Gray Matter	Learning, Normal Mapping	Normals	10
8050057	4	2007	16603709	Neither	Gray Matter	Learning, Normal Mapping	Normals	10
8050058	1	2007	16740583	Neither	White Matter	Linguistic Effects	Normals	21
8050058	2	2007	16740583	Neither	White Matter	Linguistic Effects	Normals	21
8050059	1	2002	12372292	Neither	Gray Matter	Learning, Linguistic Effects	Normals	59
8050059	2	2002	12372292	Neither	White Matter	Learning, Linguistic Effects	Normals	59
8050060	1	2001	11525331	Neither	Gray Matter	Age Effects	Normals	29
8050060	2	2001	11525331	Neither	Gray Matter	Age Effects	Normals	29
8050060	3	2001	11525331	Neither	Gray Matter	Age Effects	Normals	29
8050060	4	2001	11525331	Neither	Gray Matter	Age Effects	Normals	29
8050061	1	2007	17268166	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Stroke	18
8050062	1	2005	15852381	Neither	Gray Matter	Age Effects	Normals	106
8050062	2	2005	15852381	Neither	Gray Matter	Age Effects	Normals	106
8050063	1	2006	16638121	Neither	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
8050063	2	2006	16638121	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
8050064	1	2007	17515793	Neither	Gray Matter	Age Effects	Normals	158
8050064	2	2007	17515793	Neither	Gray Matter	Age Effects	Normals	158
8050065	1	2007	17536002	Increases in Patients	White Matter	Disease Effects	Normals, Obesity	16
8050065	2	2007	17536002	Neither	White Matter	Treatment Effects	Obesity	30
8050065	3	2007	17536002	Neither	White Matter	Disease Effects	Obesity	30
8050065	4	2007	17536002	Neither	White Matter	Disease Effects	Obesity	30
8050066	1	2006	16214373	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	19
8050067	1	2006	16404228	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	61
8050068	1	2006	17113049	Neither	Gray Matter	Normal Mapping	Normals	56
8050068	2	2006	17113049	Neither	Gray Matter	Normal Mapping	Normals	56
8050068	3	2006	17113049	Neither	Gray Matter	Normal Mapping	Normals	56
8050069	1	2007	null	Neither	Gray Matter	Disease Effects, Drug Effects	Breast Cancer	51
8050069	2	2007	null	Neither	White Matter	Disease Effects, Drug Effects	Breast Cancer	51
8050070	1	2001	11522573	Increases in Controls	Gray Matter	Learning, Normal Mapping	Preterm Birth	12
8050071	1	2004	15588309	Increases in Patients	White Matter	Disease Effects	Developmental Stuttering, Normals	10
8050072	1	2006	16773268	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	3
8050073	1	2006	16534122	Increases in Controls	Gray Matter	Disease Effects	Normals, Traumatic Spinal Cord Injury	17
8050074	1	2007	17011096	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
8050075	1	2004	14742591	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	22
8050076	1	2002	12084891	Increases in Controls	Gray Matter	Disease Effects	Narcolepsy, Normals	12
8050077	1	2006	16550383	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	30
8050078	1	2007	17045492	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	30
8050079	1	2002	12498745	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	16
8050079	2	2002	12498745	Increases in Controls	Gray Matter	Disease Effects	Nonschizophrenia Psychosis, Normals	16
8050079	3	2002	12498745	Neither	Gray Matter	Disease Effects	Nonschizophrenia Psychosis, Schizophrenia	16
8050080	1	2005	15961045	Neither	Gray Matter	Normal Mapping	Normals	24
8050081	1	2004	15540637	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	11
8050081	2	2004	15540637	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder, Normals	9
8050081	3	2004	15540637	Neither	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder, Normals	9
8050082	1	2005	15679539	Neither	Gray Matter	Normal Mapping	Normals	30
8050082	2	2005	15679539	Neither	Gray Matter	Age Effects	Normals	30
8050083	1	2006	16543808	Neither	Gray Matter	Age Effects	Normals	17
8050083	2	2006	16543808	Increases in Controls	White Matter	Age Effects	Normals	17
8050084	1	2006	16838824	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	12
8050085	1	2004	15184034	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	4
8050085	2	2004	15184034	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	4
8050085	3	2004	15184034	Neither	Gray Matter	Gender Effects, Disease Effects	Bipolar Disorder	4
8050085	4	2004	15184034	Neither	Gray Matter	Gender Effects, Disease Effects	Bipolar Disorder	4
8050085	5	2004	15184034	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	4
8050085	6	2004	15184034	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	4
8050085	7	2004	15184034	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	4
8050086	1	2004	15013835	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	39
8050087	1	2003	12611840	Increases in Controls	Gray Matter	Disease Effects	Normals, Panic Disorder	18
8050088	1	2005	15713712	Neither	Gray Matter	Drug Effects	Obesity	3
8050088	2	2005	15713712	Neither	Gray Matter	Drug Effects	Obesity	3
8050089	1	1999	10395332	Increases in Patients	Gray Matter	Disease Effects	Idiopathic Headache Disorder, Normals	25
8050090	1	2004	15476683	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	26
8050090	3	2004	15476683	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	19
8050090	5	2004	15476683	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	24
8050091	1	2004	15325363	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	13
8050091	2	2004	15325363	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
8050091	3	2004	15325363	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	13
8050091	4	2004	15325363	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
8050092	1	2004	15483594	Neither	Gray Matter	Linguistic Effects	Normals	25
8050092	2	2004	15483594	Neither	Gray Matter	Linguistic Effects	Normals	25
8050092	3	2004	15483594	Neither	Gray Matter	Linguistic Effects	Normals	25
8050092	4	2004	15483594	Neither	Gray Matter	Linguistic Effects	Normals	25
8050093	1	2007	17088334	Increases in Controls	Gray Matter	Drug Effects	Alcoholism, Normals	22
8050093	2	2007	17088334	Increases in Controls	White Matter	Drug Effects	Alcoholism, Normals	22
8050094	1	2005	15860335	Increases in Controls	Gray Matter	Disease Effects	Anxiety, Normals	17
8050095	1	2006	16686655	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	26
8050095	2	2006	16686655	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	26
8050095	3	2006	16686655	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	26
8050095	4	2006	16686655	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	26
8050096	1	2007	17024326	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	46
8050096	2	2007	17024326	Neither	Gray Matter	Disease Effects	Huntington's Disease, Normals	46
8050097	1	2005	15668417	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	19
8050097	2	2005	15668417	Neither	Gray Matter	Disease Effects	Parkinson's Disease	9
8050097	3	2005	15668417	Neither	Gray Matter	Disease Effects	Parkinson's Disease	9
8050097	4	2005	15668417	Neither	Gray Matter	Disease Effects	Parkinson's Disease	19
8050098	7	2006	16256376	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	16
8050098	8	2006	16256376	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	20
8050098	9	2006	16256376	Neither	Gray Matter	Drug Effects, Disease Effects	Bipolar Disorder	16
8050099	1	2001	11673161	Increases in Controls	Gray Matter	Age Effects	Normals	22
8050099	2	2001	11673161	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	22
8050100	1	2004	15461817	Increases in Controls	Gray Matter	Disease Effects	Fatigue, Normals	16
8050101	1	2005	16272876	Neither	Gray Matter	Normal Mapping	Normals	41
8050101	2	2005	16272876	Neither	Gray Matter	Normal Mapping	Normals	41
8050101	3	2005	16272876	Neither	Gray Matter	Normal Mapping	Normals	41
8050102	1	2006	16306152	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	14
8050103	1	2006	16545583	Increases in Patients	Gray Matter	Disease Effects	Normals, Obesity	24
8050103	2	2006	16545583	Increases in Controls	Gray Matter	Disease Effects	Normals, Obesity	24
8050103	3	2006	16545583	Increases in Patients	White Matter	Disease Effects	Normals, Obesity	24
8050104	1	2007	17123711	Neither	Gray Matter	Normal Mapping	Normals, Obesity	16
8050104	2	2007	17123711	Neither	Gray Matter	Normal Mapping	Normals, Obesity	16
8050105	1	2005	15607988	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	32
8050106	1	2007	17033628	Neither	Gray Matter	Disease Effects	Schizophrenia	15
8050106	2	2007	17033628	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	12
8050107	1	2006	16203159	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	34
8050108	1	2006	16806975	Increases in Controls	Gray Matter	Disease Effects	Facioscapulohumeral Dystrophy, Normals	30
8050109	1	2006	17008334	Neither	Gray Matter	Disease Effects	Dementia, Normals	20
8050109	2	2006	17008334	Neither	Gray Matter	Disease Effects	Dementia, Normals	20
8050109	3	2006	17008334	Neither	Gray Matter	Disease Effects	Dementia, Normals	20
8050110	1	2006	16154603	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment	1
8050110	2	2006	16154603	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment	1
8050111	1	2007	17462915	Neither	Gray Matter	Disease Effects	Stroke	10
8050111	2	2007	17462915	Increases in Controls	Gray Matter	Disease Effects	Normals, Stroke	10
8050112	1	2004	15260365	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	20
8050114	1	2003	12814586	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	13
8050114	2	2003	12814586	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	13
8050114	3	2003	12814586	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	13
8050115	1	2004	15006650	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	14
8050116	2	2005	15548553	Increases in Controls	White Matter	Disease Effects	Normals, Traumatic Head Injury	31
8050117	1	2005	16101758	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	13
8050117	2	2005	16101758	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	13
8050118	1	2000	11098800	Increases in Controls	Gray Matter	Disease Effects	Developmental Amnesia, Normals	5
8050118	2	2000	11098800	Increases in Controls	Gray Matter	Disease Effects	Developmental Amnesia, Normals	5
8050118	3	2000	11098800	Increases in Controls	Gray Matter	Disease Effects	Developmental Amnesia, Normals	5
8050119	1	2006	16966547	Increases in Controls	Gray Matter	Age Effects, Disease Effects	Developmental Amnesia, Normals	40
8050119	2	2006	16966547	Increases in Controls	Gray Matter	Age Effects, Normal Mapping	Normals	40
8050119	3	2006	16966547	Increases in Controls	Gray Matter	Age Effects, Disease Effects	Developmental Amnesia, Normals	40
8050120	1	2007	16876824	Increases in Controls	Gray Matter	Disease Effects	Normals, Pedophilia	18
8050120	2	2007	16876824	Neither	Gray Matter	Disease Effects	Normals, Pedophilia	18
8050120	3	2007	16876824	Neither	Gray Matter	Disease Effects	Normals, Pedophilia	18
8050121	1	2006	16839305	Neither	Gray Matter	Age Effects	Normals	13
8050121	2	2006	16839305	Neither	Gray Matter	Age Effects	Normals	13
8050122	1	2006	16750298	Increases in Patients	Gray Matter	Disease Effects	Chronic Lower Back Pain, Normals	18
8050122	2	2006	16750298	Increases in Controls	Gray Matter	Disease Effects	Chronic Lower Back Pain, Normals	18
8050122	3	2006	16750298	Neither	Gray Matter	Disease Effects	Chronic Lower Back Pain	18
8050122	4	2006	16750298	Neither	Gray Matter	Disease Effects	Chronic Lower Back Pain	18
8050122	5	2006	16750298	Neither	Gray Matter	Disease Effects	Chronic Lower Back Pain	18
8050124	1	2007	17299505	Increases in Controls	Gray Matter	Drug Effects	Cocaine-Dependent, Normals	40
8050124	2	2007	17299505	Increases in Controls	White Matter	Drug Effects	Cocaine-Dependent, Normals	40
8050125	1	2001	11234756	Increases in Controls	Gray Matter	Drug Effects, Disease Effects	Fetal Alcohol Syndrome, Normals, Prenatal Alcohol Exposure	7
8050125	2	2001	11234756	Increases in Controls	White Matter	Drug Effects, Disease Effects	Fetal Alcohol Syndrome, Normals, Prenatal Alcohol Exposure	7
8050125	3	2001	11234756	Increases in Controls	Gray Matter	Drug Effects, Disease Effects	Fetal Alcohol Syndrome, Normals	14
8050125	4	2001	11234756	Increases in Controls	Gray Matter	Drug Effects, Disease Effects	Normals, Prenatal Alcohol Exposure	7
8050126	1	2003	14511797	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	28
8050127	1	2003	14568814	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050127	2	2003	14568814	Increases in Controls	White Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050127	3	2003	14568814	Increases in Patients	White Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050128	1	2005	15734363	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050128	2	2005	15734363	Increases in Controls	White Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050128	3	2005	15734363	Increases in Patients	White Matter	Disease Effects	Multiple-System Atrophy, Normals	13
8050129	1	2006	16996749	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals, Pervasive Developmental Disorder	15
8050129	2	2006	16996749	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals, Pervasive Developmental Disorder	15
8050129	3	2006	16996749	Increases in Patients	White Matter	Disease Effects	Autism Spectrum Disorder, Normals, Pervasive Developmental Disorder	15
8050129	4	2006	16996749	Neither	Gray Matter	Disease Effects	Normals, Pervasive Developmental Disorder	16
8050129	5	2006	16996749	Neither	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
8050131	1	2005	15710857	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	13
8050131	2	2005	15710857	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	13
8050131	3	2005	15710857	Neither	Gray Matter	Disease Effects	Parkinson's Disease	13
8050132	1	2005	15238436	Neither	Gray Matter	Age Effects	Normals	23
8050132	2	2005	15238436	Neither	Gray Matter	Age Effects	Normals	23
8050133	1	2006	16969045	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	19
8050134	1	2006	16737464	Neither	Gray Matter	Drug Effects	Normals	405
8050135	1	2005	16150493	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	13
8050137	1	2004	14994294	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	7
8050138	1	2004	15115735	Increases in Controls	Gray Matter	Age Effects	Normals	38
8050138	2	2004	15115735	Increases in Controls	Gray Matter	Age Effects	Normals	37
8050141	1	2005	16307590	Increases in Controls	Gray Matter	Disease Effects	Albinism, Normals	19
8050141	2	2005	16307590	Increases in Controls	Gray Matter	Disease Effects	Albinism, Normals	19
8050142	1	2006	16703329	Increases in Controls	Gray Matter	Disease Effects	Type I Diabetes	13
8050143	1	2003	14527599	Increases in Controls	Gray Matter	Disease Effects	Down Syndrome, Normals	11
8050143	2	2003	14527599	Increases in Patients	Gray Matter	Disease Effects	Down Syndrome, Normals	11
8050143	3	2003	14527599	Increases in Controls	White Matter	Disease Effects	Down Syndrome, Normals	11
8050143	4	2003	14527599	Increases in Patients	White Matter	Disease Effects	Down Syndrome, Normals	11
8050143	5	2003	14527599	Increases in Controls	CSI	Disease Effects	Down Syndrome, Normals	11
8050143	6	2003	14527599	Increases in Patients	CSI	Disease Effects	Down Syndrome, Normals	11
8050144	1	2006	16677830	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	41
8050144	2	2006	16677830	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	41
8050144	3	2006	16677830	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
8050145	1	2007	16797786	Increases in Controls	Gray Matter	Disease Effects	Normals, Posterior Cortical Atrophy	38
8050145	2	2007	16797786	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	38
8050145	3	2007	16797786	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Posterior Cortical Atrophy	38
8050145	4	2007	16797786	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Posterior Cortical Atrophy	38
8050146	1	2001	11304078	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	48
8050146	2	2001	11304078	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	48
8050146	3	2001	11304078	Increases in Controls	CSI	Disease Effects	Normals, Schizophrenia	48
8050146	4	2001	11304078	Increases in Patients	CSI	Disease Effects	Normals, Schizophrenia	48
8050146	5	2001	11304078	Neither	Gray Matter	Disease Effects	Schizophrenia	48
8050147	1	2006	17030756	Neither	Gray Matter	Normal Mapping	Normals	27
8050149	1	2007	17988358	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	15
8050150	1	2005	16262646	Increases in Controls	Gray Matter	Disease Effects	Normals, Panic Disorder	18
8050151	1	2006	16413757	Increases in Patients	Gray Matter	Drug Effects	Schizophrenia	15
8050151	2	2006	16413757	Neither	Gray Matter	Drug Effects, Disease Effects	Schizophrenia	15
8050151	3	2006	16413757	Neither	White Matter	Disease Effects, Drug Effects	Schizophrenia	15
8060152	1	2006	17071925	Increases in Controls	Gray Matter	Disease Effects	Aphasia, Normals	7
8060153	1	2007	17370339	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	18
8060153	2	2007	17370339	Increases in Patients	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	18
8060153	3	2007	17370339	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	18
8060154	1	2005	16039619	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	40
8060154	2	2005	16039619	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	40
8060154	3	2005	16039619	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	40
8060155	1	2005	16157746	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	4
8060155	2	2005	16157746	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	4
8060155	3	2005	16157746	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	10
8060155	4	2005	16157746	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	4
8060155	5	2005	16157746	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	4
8060155	6	2005	16157746	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	4
8060156	1	2003	12599277	Increases in Controls	Gray Matter	Disease Effects	Dyspraxia, Normals	10
8060156	2	2003	12599277	Increases in Patients	Gray Matter	Disease Effects	Dyspraxia, Normals	10
8060156	3	2003	12599277	Increases in Controls	Gray Matter	Disease Effects	Dyspraxia, Normals	7
8060156	4	2003	12599277	Increases in Patients	Gray Matter	Disease Effects	Dyspraxia, Normals	7
8060156	5	2003	12599277	Increases in Controls	Gray Matter	Disease Effects	Dyspraxia, Normals	10
8060156	6	2003	12599277	Increases in Patients	Gray Matter	Disease Effects	Dyspraxia, Normals	10
8060156	7	2003	12599277	Increases in Controls	Gray Matter	Disease Effects	Dyspraxia, Normals	7
8060156	8	2003	12599277	Increases in Patients	Gray Matter	Disease Effects	Dyspraxia, Normals	7
8060157	1	2004	15001679	Neither	Gray Matter	Age Effects	Normals	14
8060158	1	2006	16317714	Neither	Gray Matter	Learning, Age Effects	Normals	19
8060159	1	2004	15325384	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
8060159	2	2004	15325384	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
8060160	1	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	2	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	3	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	4	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	5	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	6	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	7	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	8	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	9	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060160	10	2006	16686656	Increases in Patients	Gray Matter	Disease Effects	Focal Cortical Dysplasia, Normals	11
8060161	1	2006	16401739	Increases in Controls	Gray Matter	Disease Effects	Corticobasal Degeneration, Normals	14
8060161	2	2006	16401739	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	15
8060161	3	2006	16401739	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Progressive Supranuclear Palsy (PSP)	14
8060161	4	2006	16401739	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Progressive Supranuclear Palsy (PSP)	14
8060163	1	2006	16569671	Neither	Gray Matter	Disease Effects	22q11.2 Deletion Syndrome	39
8060163	2	2006	16569671	Neither	Gray Matter	Disease Effects	22q11.2 Deletion Syndrome	39
8060163	3	2006	16569671	Neither	Gray Matter	Disease Effects	22q11.2 Deletion Syndrome	39
8060164	1	2005	16129560	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	25
8060166	1	2005	16009889	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration, Normals	10
8060166	2	2005	16009889	Neither	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration	10
8060167	1	2005	15979341	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	7
8060167	2	2005	15979341	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	7
8060168	1	2006	16513370	Neither	Gray Matter	Age Effects	Normals	23
8060169	1	2004	14737157	Neither	Gray Matter	Learning	Normals	12
8060170	3	2005	15871596	Increases in Controls	Gray Matter	Disease Effects	Dyslexia, Normals	13
8060171	1	2006	16806978	Increases in Patients	Gray Matter	Disease Effects	Normals, Williams Syndrome	8
8060171	2	2006	16806978	Increases in Controls	Gray Matter	Disease Effects	Normals, Williams Syndrome	8
8060171	3	2006	16806978	Increases in Controls	Gray Matter	Disease Effects	Normals, Williams Syndrome	8
8060171	4	2006	16806978	Increases in Patients	Gray Matter	Disease Effects	Normals, Williams Syndrome	8
8060172	1	2005	15670702	Increases in Patients	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	28
8060172	2	2005	15670702	Increases in Controls	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	28
8060172	3	2005	15670702	Increases in Patients	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	23
8060172	4	2005	15670702	Increases in Patients	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	23
8060173	1	2002	12147312	Neither	Gray Matter	Normal Mapping	Normals	17
8060175	1	2006	16434999	Increases in Controls	Gray Matter	Normal Mapping	Normals	16
8060175	2	2006	16434999	Increases in Controls	White Matter	Normal Mapping	Normals	16
8060176	1	2002	11822992	Increases in Controls	Gray Matter	Drug Effects	Normals, Recreational Drug Users	13
8060177	1	2006	17004938	Increases in Controls	Gray Matter	Drug Effects	Normals, Smokers	22
8060177	2	2006	17004938	Increases in Controls	Gray Matter	Drug Effects	Normals, Smokers	22
8060178	1	2006	16437578	Increases in Patients	Gray Matter	Disease Effects	Normals, Tourette Syndrome	31
8060179	1	2006	16488626	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	58
8060179	2	2006	16488626	Neither	Gray Matter	Age Effects, Normal Mapping	Normals	58
8060180	1	2006	16809052	Increases in Controls	White Matter	Disease Effects	Normals, Preterm Birth	50
8060180	2	2006	16809052	Increases in Controls	White Matter	Disease Effects	Normals, Preterm Birth	50
8060180	3	2006	16809052	Neither	White Matter	Disease Effects, Age Effects	Preterm Birth	50
8060180	4	2006	16809052	Neither	White Matter	Disease Effects	Preterm Birth	50
8060180	5	2006	16809052	Neither	White Matter	Disease Effects, Age Effects	Preterm Birth	50
8060180	6	2006	16809052	Neither	White Matter	Disease Effects	Preterm Birth	50
8060183	1	2005	15850735	Neither	Gray Matter	Normal Mapping	Normals	25
8060183	2	2005	15850735	Neither	Gray Matter	Normal Mapping	Normals	25
8060183	3	2005	15850735	Neither	Gray Matter	Normal Mapping	Normals	25
8060184	1	2001	11506541	Neither	Gray Matter	Normal Mapping	Normals	38
8060184	2	2001	11506541	Neither	Gray Matter	Gender Effects	Normals	29
8060184	3	2001	11506541	Neither	Gray Matter	Gender Effects	Normals	29
8060184	4	2001	11506541	Neither	White Matter	Normal Mapping	Normals	38
8060184	5	2001	11506541	Neither	White Matter	Gender Effects	Normals	29
8060184	6	2001	11506541	Neither	White Matter	Gender Effects	Normals	29
8060184	7	2001	11506541	Neither	White Matter	Gender Effects	Normals	29
8060184	8	2001	11506541	Neither	White Matter	Gender Effects	Normals	29
8060185	1	2004	14991811	Increases in Controls	Gray Matter	Disease Effects	Aphasia, Normals	10
8060185	2	2004	14991811	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	10
8060185	3	2004	14991811	Increases in Controls	Gray Matter	Disease Effects	Aphasia, Normals	10
8060186	1	2006	16931509	Increases in Patients	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	5
8060186	2	2006	16931509	Increases in Patients	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	6
8060186	3	2006	16931509	Increases in Patients	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	5
8060186	4	2006	16931509	Increases in Patients	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	6
8060186	5	2006	16931509	Increases in Patients	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	5
8060187	1	2003	12600721	Neither	Gray Matter	Age Effects	Normals	24
8060188	1	2005	15852395	Neither	Gray Matter	Disease Effects	Dementia	17
8060188	2	2005	15852395	Neither	Gray Matter	Disease Effects	Dementia	17
8060188	3	2005	15852395	Neither	Gray Matter	Disease Effects	Dementia	17
8060189	1	2005	15734366	Neither	Gray Matter	Normal Mapping	Normals	22
8060189	2	2005	15734366	Neither	Gray Matter	Normal Mapping	Normals	26
8060189	3	2005	15734366	Neither	White Matter	Normal Mapping	Normals	22
8060189	4	2005	15734366	Neither	White Matter	Normal Mapping	Normals	26
8060190	1	2004	15079017	Increases in Controls	Gray Matter	Disease Effects	Corticobasal Degeneration, Normals	5
8060190	2	2004	15079017	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	3
8060193	1	2006	16818862	Neither	Gray Matter	Normal Mapping	Normals	80
8060193	2	2006	16818862	Neither	Gray Matter	Disease Effects	Schizophrenia	183
8060194	1	2006	16807330	Increases in Patients	Gray Matter	Disease Effects	Normals, Turner Syndrome	10
8060194	2	2006	16807330	Increases in Controls	Gray Matter	Disease Effects	Normals, Turner Syndrome	10
8060195	1	2007	17512782	Increases in Patients	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	14
8060196	1	2001	11735840	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	158
8060196	2	2001	11735840	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	158
8060196	3	2001	11735840	Increases in Controls	Gray Matter	Age Effects	Normals	158
8060196	4	2001	11735840	Increases in Patients	Gray Matter	Age Effects	Schizophrenia	159
8060197	1	2004	14741639	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	158
8060197	2	2004	14741639	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	158
8060198	1	2003	12783423	Neither	Gray Matter	Disease Effects	Preterm Birth	11
8060198	2	2003	12783423	Neither	White Matter	Disease Effects	Preterm Birth	11
8060200	1	2007	17010420	Increases in Controls	White Matter	Disease Effects	Developmental Language Disorder, Normals	21
8060201	1	2005	15850721	Neither	Gray Matter	Normal Mapping	Normals	19
8060201	2	2005	15850721	Neither	Gray Matter	Normal Mapping	Normals	65
8060201	3	2005	15850721	Neither	Gray Matter	Normal Mapping	Normals	19
8060201	4	2005	15850721	Neither	Gray Matter	Normal Mapping	Normals	65
8060202	1	2003	14511796	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	34
8060202	2	2003	14511796	Neither	Gray Matter	Normal Mapping	Normals	36
8060204	1	2002	11969314	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	40
8060204	2	2002	11969314	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	40
8060204	3	2002	11969314	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	36
8060204	4	2002	11969314	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	36
8060205	5	2004	15528086	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	40
8060205	6	2004	15528086	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	40
8060205	7	2004	15528086	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	36
8060205	8	2004	15528086	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	36
8060206	1	2002	12438464	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	58
8060206	2	2002	12438464	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	58
8060206	3	2002	12438464	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	58
8060206	4	2002	12438464	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	58
8060206	5	2002	12438464	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	58
8060206	6	2002	12438464	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	58
8060206	7	2002	12438464	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	58
8060206	8	2002	12438464	Increases in Patients	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	58
8060206	9	2002	12438464	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	58
8060207	1	2006	15982446	Increases in Controls	Gray Matter	Drug Effects	Normals, Recreational Drug Users	20
8060209	1	2006	16648537	Increases in Patients	Gray Matter	Disease Effects	Normals, Tourette Syndrome	14
8060209	2	2006	16648537	Increases in Controls	Gray Matter	Disease Effects	Normals, Tourette Syndrome	14
8060211	1	2006	16369836	Increases in Controls	Gray Matter	Drug Effects	Normals, Recreational Drug Users	46
8060212	1	2003	12694890	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	27
8060212	2	2003	12694890	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	27
8060212	3	2003	12694890	Increases in Controls	Gray Matter	Normal Mapping	Normals	27
8060212	4	2003	12694890	Neither	Gray Matter	Normal Mapping	Normals	27
8060212	5	2003	12694890	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	31
8060212	6	2003	12694890	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	31
8060213	1	2005	15607838	Increases in Controls	Gray Matter	Drug Effects	Normals, Recreational Drug Users	8
8060213	2	2005	15607838	Increases in Controls	White Matter	Drug Effects	Normals, Recreational Drug Users	8
8060213	3	2005	15607838	Increases in Patients	Gray Matter	Drug Effects	Normals, Recreational Drug Users	8
8060213	4	2005	15607838	Increases in Patients	White Matter	Drug Effects	Normals, Recreational Drug Users	8
8060214	1	2003	12880835	Increases in Controls	Gray Matter	Drug Effects	Cocaine-Dependent, Normals	11
8060214	2	2003	12880835	Neither	White Matter	Drug Effects	Cocaine-Dependent	14
8060215	1	2006	17097276	Neither	Gray Matter	Drug Effects	Schizophrenia	8
8060215	2	2006	17097276	Neither	Gray Matter	Drug Effects	Schizophrenia	8
8060216	1	2006	16342281	Neither	Gray Matter	Disease Effects	Bipolar Disorder, Normals, Schizophrenia	19
8060216	2	2006	16342281	Neither	White Matter	Disease Effects	Bipolar Disorder, Normals, Schizophrenia	19
8060217	1	2004	15054057	Increases in Controls	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8060217	2	2004	15054057	Increases in Patients	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8060217	3	2004	15054057	Increases in Controls	White Matter	Disease Effects	Normals, Turner Syndrome	14
8060217	4	2004	15054057	Increases in Patients	White Matter	Disease Effects	Normals, Turner Syndrome	14
8060217	5	2004	15054057	Increases in Patients	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8060217	6	2004	15054057	Increases in Patients	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8060217	7	2004	15054057	Increases in Controls	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8060218	1	2006	16360321	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	19
8060218	2	2006	16360321	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	19
8060218	3	2006	16360321	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis	19
8060219	1	2006	16280464	Increases in Controls	Gray Matter	Disease Effects	Normals, Tinnitus	28
8060220	1	2000	10632099	Increases in Patients	Gray Matter	Disease Effects	Dementia, Normals	6
8060221	1	2007	17443700	Increases in Patients	Gray Matter	Disease Effects	Dystonia, Normals	9
8060221	2	2007	17443700	Increases in Controls	Gray Matter	Disease Effects	Dystonia, Normals	9
8060221	3	2007	17443700	Increases in Patients	Gray Matter	Disease Effects	Dystonia, Normals	11
8060221	4	2007	17443700	Increases in Controls	Gray Matter	Disease Effects	Dystonia, Normals	11
8060222	1	2004	15163693	Increases in Controls	Gray Matter	Disease Effects	Normals, Williams Syndrome	40
8060222	2	2004	15163693	Increases in Patients	Gray Matter	Disease Effects	Normals, Williams Syndrome	40
8060223	1	2006	16728687	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	15
8060223	2	2006	16728687	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	15
8060223	3	2006	16728687	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	15
8060224	1	2002	11805245	Increases in Patients	Gray Matter	Disease Effects	Dementia, Normals	8
8060224	2	2002	11805245	Neither	Gray Matter	Disease Effects	Dementia, Normals	8
8060224	3	2002	11805245	Neither	Gray Matter	Disease Effects	Dementia, Normals	8
8060225	1	2006	16502217	Increases in Controls	Gray Matter	Disease Effects	Normals, White Matter Hyperintensity	39
8060225	2	2006	16502217	Increases in Controls	Gray Matter	Age Effects, Disease Effects	Normals, White Matter Hyperintensity	14
8060226	1	2006	16796705	Neither	Gray Matter	Drug Effects	Normals	12
8060227	1	2005	15975942	Increases in Controls	Gray Matter	Disease Effects	Dyslexia, Normals	9
8060227	2	2005	15975942	Increases in Patients	Gray Matter	Disease Effects	Dyslexia, Normals	9
8060227	3	2005	15975942	Neither	Gray Matter	Disease Effects	Dyslexia	10
8060227	4	2005	15975942	Increases in Controls	White Matter	Disease Effects	Dyslexia, Normals	9
8060228	1	2004	14985261	Neither	Gray Matter	Disease Effects, Age Effects	Down Syndrome	27
8060228	2	2004	14985261	Neither	Gray Matter	Disease Effects, Age Effects	Down Syndrome	27
8060229	1	2005	15978549	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
8060229	2	2005	15978549	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
8060229	3	2005	15978549	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
8060229	4	2005	15978549	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
8060231	1	2002	11872605	Increases in Controls	Gray Matter	Disease Effects	Normals, Verbal Dyspraxia	10
8060231	2	2002	11872605	Increases in Patients	Gray Matter	Disease Effects	Normals, Verbal Dyspraxia	10
8060231	3	2002	11872605	Increases in Controls	Gray Matter	Linguistic Effects	Normals, Verbal Dyspraxia	7
8060231	4	2002	11872605	Increases in Patients	Gray Matter	Disease Effects	Normals, Verbal Dyspraxia	7
8090152	1	2007	16960651	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	30
8090152	2	2007	16960651	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	30
8090152	3	2007	16960651	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	30
8090152	4	2007	16960651	Neither	Gray Matter	Disease Effects	Schizophrenia	50
8090153	2	2007	17709706	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Parkinson's Disease	15
8090154	1	2007	17370345	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	36
8090154	2	2007	17370345	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	36
8090154	3	2007	17370345	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	36
8090156	1	2007	17012334	Increases in Controls	Gray Matter	Normal Mapping	Normals	49
8090156	2	2007	17012334	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	19
8090156	3	2007	17012334	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	17
8090156	4	2007	17012334	Increases in Patients	Gray Matter	Disease Effects	Epilepsy	17
8090156	5	2007	17012334	Increases in Patients	Gray Matter	Disease Effects	Epilepsy	17
8090156	6	2007	17012334	Increases in Patients	Gray Matter	Disease Effects	Epilepsy	17
8090157	1	2006	16872843	Neither	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	36
8090157	2	2006	16872843	Neither	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	36
8090158	1	2004	14706428	Increases in Controls	Gray Matter	Drug Effects	Normals, Smokers	17
8090160	1	2005	16093315	Neither	Gray Matter	Normal Mapping	Normals	13
8090160	2	2005	16093315	Neither	Gray Matter	Normal Mapping	Normals	13
8090160	3	2005	16093315	Neither	Gray Matter	Normal Mapping	Normals	13
8090161	1	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	32
8090161	2	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	16
8090161	3	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	32
8090161	4	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	16
8090161	5	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	32
8090161	6	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	16
8090161	7	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	32
8090161	8	2006	17032778	Neither	Gray Matter	Normal Mapping	Normals	16
8090163	1	2005	16006149	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	20
8090163	2	2005	16006149	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	10
8090163	3	2005	16006149	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	10
8090164	1	2006	17060572	Neither	Gray Matter	Disease Effects	Essential Tremor, Normals	13
8090165	1	2006	16251504	Neither	Gray Matter	Normal Mapping	Normals	19
8090165	2	2006	16251504	Neither	White Matter	Normal Mapping	Normals	19
8090166	1	2007	17404777	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	18
8090166	2	2007	17404777	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	18
8090166	3	2007	17404777	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease	18
8090166	4	2007	17404777	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	18
8090166	5	2007	17404777	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	18
8090167	1	2006	16537567	Neither	Gray Matter	Disease Effects	Epilepsy	11
8090167	2	2006	16537567	Neither	Gray Matter	Disease Effects	Epilepsy	11
8090169	1	2008	17973326	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	23
8090169	2	2008	17973326	Neither	Gray Matter	Disease Effects	Parkinson's Disease	23
8090170	1	2002	12438466	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	26
8090170	2	2002	12438466	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	26
8090170	3	2002	12438466	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	29
8090172	1	2005	16180630	Neither	Gray Matter	Age Effects	Normals	9
8090172	2	2005	16180630	Neither	Gray Matter	Age Effects	Normals	9
8090173	1	2005	15627574	Neither	Gray Matter	Normal Mapping	Normals	18
8090173	2	2005	15627574	Neither	Gray Matter	Normal Mapping	Normals	18
8090173	3	2005	15627574	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	18
8090173	4	2005	15627574	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	18
8090173	5	2005	15627574	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	18
8090173	6	2005	15627574	Neither	White Matter	Normal Mapping	Normals	18
8090173	7	2005	15627574	Neither	White Matter	Normal Mapping, Age Effects	Normals	18
8090173	8	2005	15627574	Neither	White Matter	Normal Mapping, Gender Effects	Normals	18
8090173	9	2005	15627574	Neither	CSI	Normal Mapping	Normals	18
8090173	10	2005	15627574	Neither	CSI	Normal Mapping, Age Effects	Normals	18
8090173	11	2005	15627574	Neither	CSI	Normal Mapping, Gender Effects	Normals	18
8090174	1	2002	12060018	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	7
8090175	1	2007	17412561	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	10
8090175	2	2007	17412561	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
8090175	3	2007	17412561	Neither	Gray Matter	Disease Effects, Treatment Effects	Temporal Lobe Epilepsy	10
8090177	1	2005	16122945	Neither	Gray Matter	Age Effects	Normals	16
8090177	2	2005	16122945	Neither	Gray Matter	Age Effects	Normals	16
8090180	1	2002	11884488	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
8090180	2	2002	11884488	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
8090180	3	2002	11884488	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
8090181	1	2007	16481564	Neither	Gray Matter	Treatment Effects	Normals	18
8090181	2	2007	16481564	Neither	Gray Matter	Treatment Effects	Normals	18
8090182	1	2003	14622587	Increases in Controls	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8090182	2	2003	14622587	Increases in Patients	Gray Matter	Disease Effects	Normals, Turner Syndrome	14
8090183	1	2005	16085427	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
8090183	2	2005	16085427	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	23
8090183	3	2005	16085427	Increases in Controls	Gray Matter	Disease Effects	Learning Disability, Normals	18
8090184	1	2003	12902311	Increases in Controls	Gray Matter	Disease Effects	Aphasia, Normals	10
8090184	2	2003	12902311	Increases in Controls	Gray Matter	Disease Effects	Aphasia, Normals	10
8090185	1	2003	14568490	Increases in Patients	Gray Matter	Disease Effects	Deaf, Normals	10
8090186	1	2004	15488416	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	12
8090186	2	2004	15488416	Neither	White Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	12
8090187	1	2005	15995795	Neither	Gray Matter	Disease Effects	Parkinson's Disease	11
8090187	2	2005	15995795	Neither	Gray Matter	Disease Effects	Parkinson's Disease	8
8090189	1	2001	11722158	Increases in Controls	Gray Matter	Disease Effects	Normals, Tuberous Sclerosis	8
8090189	2	2001	11722158	Increases in Controls	White Matter	Disease Effects	Normals, Tuberous Sclerosis	8
8090189	3	2001	11722158	Increases in Patients	White Matter	Disease Effects	Normals, Tuberous Sclerosis	8
8090190	1	2005	15766634	Increases in Controls	White Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	18
8090190	2	2005	15766634	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder, Schizophrenia	18
8090190	3	2005	15766634	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder, Schizophrenia	18
8090191	1	2005	16195246	Neither	Gray Matter	Disease Effects	Dementia	148
8090191	2	2005	16195246	Neither	Gray Matter	Disease Effects	Dementia	148
8090191	3	2005	16195246	Neither	Gray Matter	Disease Effects	Dementia	148
8090191	4	2005	16195246	Neither	Gray Matter	Disease Effects	Dementia	148
8090191	5	2005	16195246	Neither	Gray Matter	Disease Effects	Dementia	148
8090193	1	2005	15734353	Increases in Controls	Gray Matter	Normal Mapping	22q11.2 Deletion Syndrome, Normals	18
8090193	2	2005	15734353	Increases in Patients	Gray Matter	Disease Effects	22q11.2 Deletion Syndrome, Normals	18
8090193	3	2005	15734353	Increases in Controls	White Matter	Disease Effects	22q11.2 Deletion Syndrome, Normals	18
8090193	4	2005	15734353	Increases in Patients	CSI	Disease Effects	22q11.2 Deletion Syndrome, Normals	18
8090195	1	2005	16243494	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	5
8090196	1	2007	17164468	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease	13
8090196	2	2007	17164468	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease	13
8090197	1	2004	15193622	Increases in Controls	Gray Matter	Age Effects	Normals	8
8090198	1	2005	15812604	Neither	Gray Matter	Disease Effects	Schizophrenia, Schizotypal Personality Disorder	13
8090199	1	2003	12904585	Increases in Controls	Gray Matter	Disease Effects	Developmental Amnesia, Normals	5
8090200	1	2005	15671856	Neither	Gray Matter	Drug Effects	Alzheimer's Disease	9
8090200	2	2005	15671856	Neither	Gray Matter	Drug Effects	Alzheimer's Disease	9
8090200	3	2005	15671856	Neither	Gray Matter	Drug Effects	Alzheimer's Disease	8
8090201	1	2001	11532891	Neither	Gray Matter	Normal Mapping	Normals	142
8090201	2	2001	11532891	Neither	Gray Matter	Normal Mapping	Normals	142
8090202	1	2005	16157747	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	9
8090202	2	2005	16157747	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	7
8090202	3	2005	16157747	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	5
8090203	1	2005	15998582	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	7
8090204	1	2006	16801648	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	13
8090204	2	2006	16801648	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	13
8090205	1	2008	17412719	Neither	Gray Matter	Normal Mapping	Normals	183
8090205	2	2008	17412719	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	183
8090205	3	2008	17412719	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	183
8090206	1	2003	14531753	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizotypal Personality Disorder	14
8090207	1	2003	12915287	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	48
8090208	1	2005	15907310	Neither	Gray Matter	Drug Effects	Normals	44
8090208	2	2005	15907310	Neither	White Matter	Drug Effects	Normals	44
9010001	1	2002	12377138	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	25
9010001	2	2002	12377138	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Dementia	25
9010002	1	2007	16997428	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	14
9010002	2	2007	16997428	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
9010002	3	2007	16997428	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	14
9010003	1	2005	15863740	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	25
9010003	2	2005	15863740	Neither	Gray Matter	Disease Effects	Bipolar Disorder, Schizophrenia	25
9010003	3	2005	15863740	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	25
9010003	4	2005	15863740	Increases in Controls	White Matter	Disease Effects	Bipolar Disorder, Normals	37
9010005	1	2006	16443764	Increases in Controls	Gray Matter	Disease Effects	Normals, Type I Diabetes	36
9010005	2	2006	16443764	Neither	Gray Matter	Disease Effects	Normals, Type I Diabetes	36
9010007	1	2005	16185716	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	25
9010007	2	2005	16185716	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	25
9010007	3	2005	16185716	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	25
9010007	4	2005	16185716	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	25
9010012	1	2002	12135972	Neither	Gray Matter	Normal Mapping	Normals	16
9010012	2	2002	12135972	Neither	Gray Matter	Normal Mapping	Normals	16
9010012	3	2002	12135972	Neither	White Matter	Normal Mapping, Age Effects	Normals	16
9010012	4	2002	12135972	Neither	White Matter	Normal Mapping, Age Effects	Normals	18
9010012	5	2002	12135972	Neither	White Matter	Normal Mapping, Age Effects	Normals	16
9010012	6	2002	12135972	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	16
9010013	1	2001	11719683	Neither	Gray Matter	Age Effects	Normals	81
9010013	2	2001	11719683	Neither	Gray Matter	Age Effects	Normals	81
9010013	3	2001	11719683	Neither	Gray Matter	Gender Effects	Normals	81
9010013	4	2001	11719683	Neither	Gray Matter	Gender Effects	Normals	81
9010015	1	2007	17187377	Increases in Controls	Gray Matter	Drug Effects	Normals, Sarin Intoxication	38
9010015	2	2007	17187377	Increases in Controls	White Matter	Drug Effects	Normals, Sarin Intoxication	38
9010015	3	2007	17187377	Increases in Controls	White Matter	Drug Effects	Normals, Sarin Intoxication	38
9010015	4	2007	17187377	Increases in Controls	White Matter	Drug Effects	Normals, Sarin Intoxication	38
9010017	1	2006	16857316	Neither	Gray Matter	Age Effects, Normal Mapping, Gender Effects	Normals	108
9010017	2	2006	16857316	Neither	White Matter	Age Effects, Normal Mapping, Gender Effects	Normals	108
9010017	3	2006	16857316	Neither	Gray Matter	Age Effects, Normal Mapping, Gender Effects	Normals	46
9010017	4	2006	16857316	Neither	White Matter	Age Effects, Normal Mapping, Gender Effects	Normals	46
9050018	1	2008	18342444	Increases in Controls	Gray Matter	Normal Mapping	Normals	10
9050019	1	2009	19073652	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	20
9050019	2	2009	19073652	Neither	Gray Matter	Disease Effects	Epilepsy	41
9050019	3	2009	19073652	Neither	Gray Matter	Disease Effects	Epilepsy	41
9050019	4	2009	19073652	Neither	Gray Matter	Disease Effects	Epilepsy	41
9050020	1	2009	18854867	Neither	Gray Matter	Normal Mapping	Normals	9
9050020	2	2009	18854867	Neither	Gray Matter	Normal Mapping	Normals	9
9050021	1	2008	18184841	Increases in Controls	White Matter	Disease Effects	Leukemia, Normals	9
9050023	1	2009	18486147	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	9
9050023	2	2009	18486147	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	9
9050023	3	2009	18486147	Increases in Patients	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	9
9050025	1	2008	18938065	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	21
9050025	2	2008	18938065	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	21
9050026	1	2009	18992375	Increases in Patients	Gray Matter	Disease Effects	Mental Retardation, Normals	5
9050026	2	2009	18992375	Increases in Controls	Gray Matter	Disease Effects	Mental Retardation, Normals	5
9050026	3	2009	18992375	Increases in Controls	White Matter	Disease Effects	Mental Retardation, Normals	5
9050026	4	2009	18992375	Increases in Controls	White Matter	Disease Effects	Mental Retardation, Normals	5
9050027	1	2008	17634216	Increases in Controls	Gray Matter	Disease Effects	Ataxia, Normals	22
9050027	2	2008	17634216	Increases in Controls	White Matter	Disease Effects	Ataxia, Normals	22
9050029	1	2008	18226551	Increases in Controls	White Matter	Disease Effects	Friedreich Ataxia, Normals	14
9050030	1	2008	18281020	Neither	Gray Matter	Normal Mapping, Drug Effects	Normals	32
9050030	2	2008	18281020	Neither	Gray Matter	Normal Mapping, Drug Effects	Normals	32
9050031	1	2009	19013250	Increases in Controls	Gray Matter	Disease Effects, Genotype Effects	Alzheimer's Disease	15
9050032	1	2008	18342953	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	20
9050032	2	2008	18342953	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	20
9050034	1	2008	18438695	Increases in Controls	Gray Matter	Disease Effects	Normals, Spinocerebellar Ataxia	15
9050034	2	2008	18438695	Increases in Controls	White Matter	Disease Effects	Normals, Spinocerebellar Ataxia	15
9050034	3	2008	18438695	Increases in Patients	CSI	Disease Effects	Normals, Spinocerebellar Ataxia	15
9050035	1	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	12
9050035	2	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	12
9050035	3	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Corticobasal Degeneration, Normals	9
9050035	4	2004	14761903	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Dementia	12
9050035	5	2004	14761903	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Corticobasal Degeneration	9
9050035	6	2004	14761903	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Dementia	12
9050035	7	2004	14761903	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Dementia	9
9050035	8	2004	14761903	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Corticobasal Degeneration	9
9050035	9	2004	14761903	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Dementia	9
9050035	10	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Normals, Semantic Dementia	8
9050035	11	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	7
9050035	12	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Non-Aphasic Frontotemporal Dementia, Normals	12
9050035	13	2004	14761903	Neither	Gray Matter	Disease Effects	Progressive Nonfluent Aphasia, Semantic Dementia	7
9050035	14	2004	14761903	Neither	Gray Matter	Disease Effects	Non-Aphasic Frontotemporal Dementia, Semantic Dementia	8
9050035	15	2004	14761903	Neither	Gray Matter	Disease Effects	Progressive Nonfluent Aphasia, Semantic Dementia	7
9050035	16	2004	14761903	Neither	Gray Matter	Disease Effects	Non-Aphasic Frontotemporal Dementia, Progressive Nonfluent Aphasia	7
9050035	17	2004	14761903	Neither	Gray Matter	Disease Effects	Non-Aphasic Frontotemporal Dementia, Semantic Dementia	8
9050035	18	2004	14761903	Neither	Gray Matter	Disease Effects	Non-Aphasic Frontotemporal Dementia, Progressive Nonfluent Aphasia	7
9050035	19	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease	12
9050035	20	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Frontotemporal Dementia	29
9050035	21	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Corticobasal Degeneration	9
9050035	22	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Semantic Dementia	8
9050035	23	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Progressive Nonfluent Aphasia	7
9050035	24	2004	14761903	Increases in Patients	Gray Matter	Disease Effects	Non-Aphasic Frontotemporal Dementia	14
9050036	1	2009	19016669	Neither	Gray Matter	Disease Effects	Schizophrenia	18
9050036	2	2009	19016669	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
9050036	3	2009	19016669	Neither	Gray Matter	Disease Effects	Schizophrenia	18
9050037	1	2008	18774263	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
9050037	2	2008	18774263	Neither	Gray Matter	Disease Effects	Schizophrenia	20
9050039	1	2008	18166704	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration	5
9050039	2	2008	18166704	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease	5
9050039	3	2008	18166704	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration	5
9050039	4	2008	18166704	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration	5
9050039	5	2008	18166704	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease	5
9050039	6	2008	18166704	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration	5
9050040	1	2008	18661129	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	13
9050040	2	2008	18661129	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	20
9050040	3	2008	18661129	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Dementia	13
9050041	1	2008	18296551	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	11
9050041	2	2008	18296551	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	11
9050042	1	2007	17955233	Neither	Gray Matter	Age Effects, Disease Effects	Alzheimer's Disease	51
9050042	2	2007	17955233	Neither	Gray Matter	Age Effects, Disease Effects, Gender Effects	Alzheimer's Disease	51
9050042	3	2007	17955233	Neither	Gray Matter	Age Effects, Disease Effects	Alzheimer's Disease	51
9050042	4	2007	17955233	Neither	Gray Matter	Age Effects, Disease Effects, Gender Effects	Alzheimer's Disease	51
9050043	1	2008	18422725	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	20
9050044	1	2008	18054834	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	55
9050044	2	2008	18054834	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	59
9050044	3	2008	18054834	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	61
9050044	4	2008	18054834	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	55
9050046	1	2008	18449954	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment, Normals	12
9050047	1	2009	18945378	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	17
9050047	2	2009	18945378	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	17
9050047	3	2009	18945378	Increases in Patients	Gray Matter	Disease Effects	Depression, Normals	17
9050048	1	2007	18006622	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	27
9050048	2	2007	18006622	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	27
9050049	1	2008	19096528	Neither	Gray Matter	Normal Mapping	Normals	13
9050051	1	2008	18272867	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	21
9050052	1	2007	17296989	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	9
9050054	1	2007	18836573	Neither	Gray Matter	Normal Mapping	Normals	218
9050054	2	2007	18836573	Neither	Gray Matter	Normal Mapping	Normals	218
9050054	3	2007	18836573	Neither	Gray Matter	Normal Mapping	Normals	211
9050055	1	2008	18042496	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	19
9050055	2	2008	18042496	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	19
9050056	1	2009	18980810	Neither	Gray Matter	Gender Effects, Normal Mapping	Normals	41
9050056	2	2009	18980810	Neither	Gray Matter	Gender Effects, Normal Mapping	Normals	41
9050056	3	2009	18980810	Neither	Gray Matter	Gender Effects, Normal Mapping	Normals	37
9050056	4	2009	18980810	Neither	Gray Matter	Gender Effects, Normal Mapping	Normals	37
9050058	1	2008	18224306	Increases in Controls	Gray Matter	Disease Effects	Blindness, Normals	11
9050058	2	2008	18224306	Increases in Controls	White Matter	Disease Effects	Blindness, Normals	11
9050060	1	2008	18678824	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
9050060	2	2008	18678824	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
9050060	3	2008	18678824	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
9050060	4	2008	18678824	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
9050062	1	2007	17587497	Increases in Controls	Gray Matter	Disease Effects	Fibromyalgia, Normals	20
9050062	2	2007	17587497	Increases in Controls	Gray Matter	Disease Effects	Fibromyalgia	20
9050062	3	2007	17587497	Increases in Controls	Gray Matter	Disease Effects	Fibromyalgia, Normals	20
9050064	1	2006	16904912	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
9050064	2	2006	16904912	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
9050064	3	2006	16904912	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
9050064	4	2006	16904912	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
9050064	5	2006	16904912	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
9050064	6	2006	16904912	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	20
9050065	1	2008	null	Increases in Controls	Gray Matter	Disease Effects	Developmental Dyslexia, Normals	7
9050065	2	2008	null	Increases in Controls	White Matter	Disease Effects	Developmental Dyslexia, Normals	7
9050065	3	2008	null	Increases in Controls	White Matter	Disease Effects	Developmental Dyslexia, Normals	7
9050066	1	2008	18223623	Neither	Gray Matter	Normal Mapping	Normals	690
9050066	2	2008	18223623	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	690
9050067	1	2009	18801475	Increases in Controls	Gray Matter	Drug Effects, Disease Effects	Normals, Recreational Drug Users	19
9050068	1	2008	18215449	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment, Normals	15
9050068	2	2008	18215449	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	23
9050069	1	2008	18662866	Increases in Controls	Gray Matter	Disease Effects	Nonschizophrenia Psychosis, Normals	12
9050069	2	2008	18662866	Increases in Controls	Gray Matter	Disease Effects, Drug Effects	Nonschizophrenia Psychosis, Normals	12
9050069	3	2008	18662866	Increases in Controls	Gray Matter	Disease Effects	Nonschizophrenia Psychosis, Normals	12
9050069	4	2008	18662866	Increases in Controls	Gray Matter	Disease Effects	Nonschizophrenia Psychosis	12
9050069	5	2008	18662866	Increases in Controls	White Matter	Disease Effects	Nonschizophrenia Psychosis, Normals	12
9050070	1	2007	17890058	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	32
9050072	1	2008	18184293	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	27
9050072	2	2008	18184293	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	27
9050072	3	2008	18184293	Neither	Gray Matter	Disease Effects	Migraines	27
9050073	1	2008	19019637	Increases in Controls	Gray Matter	Disease Effects	Schizophrenia	30
9050073	2	2008	19019637	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	27
9050074	1	2008	18793730	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
9050074	2	2008	18793730	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
9050075	1	2008	18592043	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	15
9050075	2	2008	18592043	Increases in Patients	Unknown	Disease Effects	Depression, Normals	15
9050075	3	2008	18592043	Increases in Patients	Gray Matter	Disease Effects	Normals	16
9050075	4	2008	18592043	Increases in Patients	Gray Matter	Disease Effects	Depression, Normals	15
9050078	1	2008	18515047	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	23
9050078	2	2008	18515047	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	23
9050079	1	2008	18434103	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	14
9050079	2	2008	18434103	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	14
9050079	3	2008	18434103	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	14
9050080	1	2009	18172852	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	12
9050081	1	2008	18518927	Neither	Gray Matter	Normal Mapping	Normals	35
9050081	2	2008	18518927	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	35
9050081	3	2008	18518927	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	35
9050081	4	2008	18518927	Neither	Gray Matter	Normal Mapping, Gender Effects, Age Effects	Normals	35
9050082	1	2008	18550031	Increases in Patients	Gray Matter	Disease Effects	Depression, Normals	16
9050082	2	2008	18550031	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	16
9050083	1	2008	19102744	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
9050083	2	2008	19102744	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	18
9050083	3	2008	19102744	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	18
9050083	4	2008	19102744	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	18
9050083	5	2008	19102744	Neither	White Matter	Disease Effects	Normals, Schizophrenia	18
9050083	6	2008	19102744	Neither	White Matter	Disease Effects	Normals, Schizophrenia	18
9050084	1	2008	18768731	Increases in Patients	Gray Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	2	2008	18768731	Increases in Controls	Gray Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	3	2008	18768731	Increases in Patients	Gray Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	4	2008	18768731	Increases in Controls	Gray Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	5	2008	18768731	Increases in Patients	Gray Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	6	2008	18768731	Increases in Controls	Gray Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	7	2008	18768731	Increases in Patients	White Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	8	2008	18768731	Increases in Controls	White Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	9	2008	18768731	Increases in Controls	White Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	10	2008	18768731	Increases in Patients	White Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	11	2008	18768731	Increases in Controls	White Matter	Disease Effects	Kallman Syndrome, Normals	16
9050084	12	2008	18768731	Increases in Patients	White Matter	Disease Effects	Kallman Syndrome, Normals	16
9050086	1	2009	19101126	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	27
9050086	2	2009	19101126	Neither	Gray Matter	Disease Effects, Gender Effects	Bipolar Disorder	27
9050086	4	2009	19101126	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	27
9050086	5	2009	19101126	Neither	Gray Matter	Disease Effects, Gender Effects	Bipolar Disorder, Normals	27
9050086	6	2009	19101126	Neither	Gray Matter	Disease Effects, Gender Effects	Bipolar Disorder, Normals	27
9050087	1	2008	18491104	Increases in Controls	Gray Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	2	2008	18491104	Increases in Controls	Gray Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	3	2008	18491104	Increases in Controls	Gray Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	4	2008	18491104	Increases in Controls	Gray Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	5	2008	18491104	Increases in Controls	White Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	6	2008	18491104	Increases in Controls	White Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	7	2008	18491104	Increases in Controls	White Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9050087	8	2008	18491104	Increases in Controls	White Matter	Disease Effects	Acute Lymphoblastic Leukemia, Normals	10
9070088	1	2009	19013533	Increases in Controls	Gray Matter	Disease Effects, Drug Effects	Multiple Sclerosis	44
9070088	2	2009	19013533	Neither	Gray Matter	Disease Effects, Drug Effects	Multiple Sclerosis	45
9080089	1	2008	19013058	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	14
9080089	2	2008	19013058	Neither	Gray Matter	Disease Effects	Depression	14
9080089	3	2008	19013058	Neither	Gray Matter	Disease Effects	Depression	14
9080090	1	2008	18226962	Neither	Gray Matter	Disease Effects	Hippocampal Sclerosis	49
9080090	2	2008	18226962	Neither	Gray Matter	Disease Effects	Hippocampal Sclerosis	49
9080090	3	2008	18226962	Neither	Gray Matter	Disease Effects	Hippocampal Sclerosis	49
9080090	4	2008	18226962	Neither	Gray Matter	Disease Effects	Hippocampal Sclerosis	40
9080090	5	2008	18226962	Neither	Gray Matter	Disease Effects	Hippocampal Sclerosis	40
9080091	1	2008	17716795	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	17
9080091	2	2008	17716795	Neither	Gray Matter	Disease Effects	Schizophrenia	17
9080091	3	2008	17716795	Neither	Gray Matter	Disease Effects	Schizophrenia	17
9080092	1	2004	15325390	Neither	Gray Matter	Normal Mapping	Normals	23
9080092	2	2004	15325390	Neither	White Matter	Normal Mapping	Normals	23
9080092	3	2004	15325390	Neither	Gray Matter	Normal Mapping	Normals	23
9080092	4	2004	15325390	Neither	White Matter	Normal Mapping	Normals	23
9080092	5	2004	15325390	Neither	Gray Matter	Normal Mapping	Normals	24
9080092	6	2004	15325390	Neither	White Matter	Normal Mapping	Normals	24
9080093	1	2008	18469033	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	41
9080093	2	2008	18469033	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	41
9080093	3	2008	18469033	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	41
9080093	4	2008	18469033	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	41
9080093	5	2008	18469033	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	41
9080098	1	2008	18378428	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	9
9080098	2	2008	18378428	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	133
9080098	3	2008	18378428	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	34
9080098	4	2008	18378428	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	21
9080099	1	2008	18703313	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	93
9080099	2	2008	18703313	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	72
9080099	3	2008	18703313	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	72
9080099	4	2008	18703313	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	72
9080099	5	2008	18703313	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	72
9080100	1	2008	18653686	Increases in Controls	Gray Matter	Disease Effects	Essential Tremor, Normals	20
9080100	2	2008	18653686	Increases in Controls	Gray Matter	Disease Effects	Essential Tremor, Normals	30
9080100	3	2008	18653686	Increases in Controls	Unknown	Disease Effects	Essential Tremor, Normals	20
9080100	4	2008	18653686	Increases in Controls	Unknown	Disease Effects	Essential Tremor, Normals	30
9080100	5	2008	18653686	Increases in Controls	Gray Matter	Disease Effects	Essential Tremor, Normals	20
9080102	1	2009	18578894	Neither	Gray Matter	Disease Effects	Schizophrenia	42
9080102	2	2009	18578894	Neither	Gray Matter	Disease Effects	Schizophrenia	42
9080102	3	2009	18578894	Neither	Gray Matter	Disease Effects	Schizophrenia	42
9080102	4	2009	18578894	Neither	Gray Matter	Disease Effects	Schizophrenia	42
9080102	5	2009	18578894	Neither	Gray Matter	Disease Effects	Schizophrenia	42
9080102	6	2009	18578894	Neither	White Matter	Disease Effects	Schizophrenia	42
9080102	7	2009	18578894	Neither	White Matter	Disease Effects	Schizophrenia	42
9080102	8	2009	18578894	Neither	White Matter	Disease Effects	Schizophrenia	42
9080102	9	2009	18578894	Neither	Gray Matter	Normal Mapping	Normals	22
9080103	1	2000	10644781	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	25
9080103	2	2000	10644781	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	25
9080103	3	2000	10644781	Neither	Gray Matter	Disease Effects	Epilepsy	25
9090104	1	2009	18266214	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	120
10010002	1	2007	17512219	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	32
10010002	2	2007	17512219	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	16
10010002	3	2007	17512219	Increases in Controls	White Matter	Disease Effects	Multiple-System Atrophy, Normals	32
10010002	4	2007	17512219	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy	16
10010002	5	2007	17512219	Increases in Controls	White Matter	Disease Effects	Multiple-System Atrophy	16
10010002	6	2007	17512219	Neither	Gray Matter	Disease Effects	Multiple-System Atrophy	32
10010002	7	2007	17512219	Neither	Gray Matter	Disease Effects	Multiple-System Atrophy	32
10010002	8	2007	17512219	Neither	Gray Matter	Disease Effects	Multiple-System Atrophy	16
10010002	9	2007	17512219	Neither	White Matter	Disease Effects	Multiple-System Atrophy	32
10010002	10	2007	17512219	Neither	White Matter	Disease Effects	Multiple-System Atrophy	32
10010004	1	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	23
10010004	2	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	23
10010004	3	2008	17504246	Neither	White Matter	Genotype Effects, Disease Effects	Schizophrenia	23
10010004	4	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	23
10010004	5	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	23
10010004	6	2008	17504246	Neither	White Matter	Genotype Effects, Disease Effects	Schizophrenia	23
10010004	7	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	9
10010004	8	2008	17504246	Neither	White Matter	Genotype Effects, Disease Effects	Schizophrenia	9
10010004	9	2008	17504246	Neither	White Matter	Genotype Effects, Disease Effects	Schizophrenia	12
10010004	10	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	5
10010004	11	2008	17504246	Neither	White Matter	Genotype Effects, Disease Effects	Schizophrenia	5
10010004	12	2008	17504246	Neither	Gray Matter	Genotype Effects, Disease Effects	Schizophrenia	17
10010004	13	2008	17504246	Neither	White Matter	Genotype Effects, Disease Effects	Schizophrenia	17
10010005	1	2007	null	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Attention Deficit/Hyperactivity Disorder, Normals	15
10010005	2	2007	null	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Attention Deficit/Hyperactivity Disorder, Normals	15
10010005	3	2007	null	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Attention Deficit/Hyperactivity Disorder, Normals	15
10010005	4	2007	null	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	15
10010005	5	2007	null	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	15
10010005	6	2007	null	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	15
10010005	7	2007	null	Increases in Patients	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	15
10010007	1	2005	15993858	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	22
10010007	2	2005	15993858	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	8
10010007	3	2005	15993858	Neither	Gray Matter	Disease Effects	Schizophrenia	25
10010007	4	2005	15993858	Neither	Gray Matter	Disease Effects	Schizophrenia	8
10010007	5	2005	15993858	Neither	Gray Matter	Disease Effects	Schizophrenia	8
10010007	6	2005	15993858	Neither	Gray Matter	Disease Effects	Schizophrenia	8
10010007	7	2005	15993858	Neither	Gray Matter	Disease Effects	Schizophrenia	8
10010007	8	2005	15993858	Neither	Gray Matter	Disease Effects	Schizophrenia	8
10010007	9	2005	15993858	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	22
10010007	10	2005	15993858	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	8
10010007	11	2005	15993858	Neither	White Matter	Disease Effects	Schizophrenia	8
10010007	12	2005	15993858	Neither	White Matter	Disease Effects	Schizophrenia	8
10010008	1	2008	17689500	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	169
10010008	2	2008	17689500	Increases in Controls	Gray Matter	Normal Mapping	Normals	212
10010008	3	2008	17689500	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	169
10010008	4	2008	17689500	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	169
10010008	5	2008	17689500	Neither	Gray Matter	Normal Mapping	Normals	212
10010008	6	2008	17689500	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	169
10010008	7	2008	17689500	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	169
10010008	8	2008	17689500	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	169
10010011	4	2009	18997157	Neither	Gray Matter	Gender Effects	Normals, Schizophrenia	88
10010012	1	2007	17296987	Neither	White Matter	Disease Effects	Deaf, Normals	51
10010012	2	2007	17296987	Neither	Gray Matter	Disease Effects	Deaf, Normals	51
10010012	3	2007	17296987	Neither	Gray Matter	Normal Mapping	Normals	51
10010012	4	2007	17296987	Neither	Gray Matter	Disease Effects	Deaf	53
10010012	5	2007	17296987	Neither	White Matter	Normal Mapping	Normals	51
10010012	6	2007	17296987	Neither	White Matter	Disease Effects	Deaf	53
10010012	7	2007	17296987	Neither	White Matter	Disease Effects	Deaf, Normals	51
10010012	8	2007	17296987	Neither	Gray Matter	Disease Effects	Deaf, Normals	51
10010013	1	2006	16894107	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	20
10010013	2	2006	16894107	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	20
10010013	3	2006	16894107	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	20
10010013	4	2006	16894107	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	22
10010013	5	2006	16894107	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	22
10010013	6	2006	16894107	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment	22
10030014	1	2009	19071222	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	21
10030015	1	2009	18718670	Increases in Controls	Gray Matter	Normal Mapping	Normals	14
10030016	1	2009	18609565	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	20
10030016	2	2009	18609565	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	20
10030019	1	2004	15371289	Neither	Gray Matter	Disease Effects	Preterm Birth	65
10030019	2	2004	15371289	Neither	Gray Matter	Disease Effects	Preterm Birth	65
10030019	3	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030019	4	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030019	5	2004	15371289	Neither	Gray Matter	Disease Effects	Preterm Birth	65
10030019	6	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030019	7	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030019	8	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030019	9	2004	15371289	Neither	Gray Matter	Disease Effects	Preterm Birth	65
10030019	10	2004	15371289	Neither	Gray Matter	Disease Effects	Preterm Birth	65
10030019	11	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030019	12	2004	15371289	Neither	White Matter	Disease Effects	Preterm Birth	65
10030021	1	2008	18819988	Neither	Gray Matter	Disease Effects	Fibromyalgia	20
10030021	2	2008	18819988	Neither	Gray Matter	Disease Effects	Fibromyalgia	20
10030021	3	2008	18819988	Neither	Gray Matter	Disease Effects	Fibromyalgia	20
10030021	4	2008	18819988	Neither	Gray Matter	Disease Effects	Fibromyalgia	20
10030021	5	2008	18819988	Neither	Gray Matter	Disease Effects	Fibromyalgia	20
10030021	6	2008	18819988	Neither	White Matter	Disease Effects	Fibromyalgia	20
10030021	7	2008	18819988	Neither	White Matter	Disease Effects	Fibromyalgia	20
10030021	8	2008	18819988	Neither	White Matter	Disease Effects	Fibromyalgia	20
10030022	1	2009	18945494	Neither	White Matter	Disease Effects	Depression, Normals	36
10030023	1	2010	20203186	Neither	Gray Matter	Normal Mapping, Handedness Effects	Normals	18
10030024	1	2009	19552926	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	12
10030025	1	2010	20042900	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	10
10030025	2	2010	20042900	Neither	Gray Matter	Age Effects	Mild Cognitive Impairment, Normals	10
10030025	3	2010	20042900	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	10
10030026	1	2010	20089342	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Dementia, Normals	5
10030027	1	2010	20167312	Neither	Gray Matter	Age Effects, Normal Mapping	Normals	228
10030028	1	2010	20065246	Neither	Gray Matter	Normal Mapping	Normals	8
10030028	2	2010	20065246	Neither	Gray Matter	Normal Mapping	Normals	16
10030028	3	2010	20065246	Neither	Gray Matter	Normal Mapping	Normals	8
10030028	4	2010	20065246	Neither	Gray Matter	Normal Mapping	Normals	8
10030028	5	2010	20065246	Neither	Gray Matter	Normal Mapping	Normals	8
10030029	1	2010	20101036	Neither	Gray Matter	Disease Effects	Normals, Post Cardiac Arrest	12
10030029	2	2010	20101036	Neither	Gray Matter	Disease Effects	Normals, Post Cardiac Arrest	12
10030029	3	2010	20101036	Neither	Gray Matter	Disease Effects	Normals, Post Cardiac Arrest	12
10030030	1	2010	20153145	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	30
10030030	2	2010	20153145	Neither	Gray Matter	Normal Mapping	Normals	14
10030031	1	2010	20035881	Increases in Patients	Gray Matter	Disease Effects	Binge-Eating, Normals	17
10030031	2	2010	20035881	Increases in Patients	Gray Matter	Disease Effects	Binge-Eating, Bulimia Nervosa	14
10030031	3	2010	20035881	Increases in Patients	Gray Matter	Disease Effects	Bulimia Nervosa, Normals	14
10030031	4	2010	20035881	Increases in Patients	Gray Matter	Disease Effects	Bulimia Nervosa	14
10030031	5	2010	20035881	Increases in Patients	Gray Matter	Disease Effects	Bulimia Nervosa	14
10030032	1	2010	20096794	Increases in Controls	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	2	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	3	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	4	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	5	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	6	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	7	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10030032	8	2010	20096794	Neither	Gray Matter	Disease Effects	Methamphetamine Dependent, Normals	44
10060033	1	2010	20392976	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	37
10060034	1	2010	20231262	Neither	Gray Matter	Disease Effects	Anosmic, Normals	17
10060035	1	2010	20213820	Neither	Gray Matter	Disease Effects	Normals, Parkinson's Disease	37
10060036	1	2010	20439824	Neither	Gray Matter	Treatment Effects	Schizophrenia	53
10060036	2	2010	20439824	Neither	Gray Matter	Treatment Effects	Schizophrenia	53
10060037	1	2010	20424827	Neither	Gray Matter	Drug Effects	Smokers	8
10060037	2	2010	20424827	Neither	Gray Matter	Drug Effects	Smokers	8
10060038	1	2004	14702264	Neither	Unknown	Disease Effects	Schizophrenia	39
10060038	2	2004	14702264	Neither	Unknown	Disease Effects	Schizophrenia	39
10060039	1	2010	20299856	Increases in Controls	Gray Matter	Disease Effects	Corticobasal Syndrome, Normals	8
10060041	1	2010	20418073	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
10060041	2	2010	20418073	Neither	Gray Matter	Disease Effects	Schizophrenia	20
10060042	1	2010	20400273	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	12
10060043	1	2010	20227249	Neither	Gray Matter	Age Effects, Disease Effects	Major Depressive Disorder (MDD), Normals	28
10060044	1	2010	20123027	Increases in Controls	Gray Matter	Disease Effects	Normals, Pervasive Developmental Disorder	32
10060046	1	2003	12593134	Increases in Controls	Gray Matter	Disease Effects	Hypoxic-Ischemic Encephalopathy, Normals	13
10060047	1	2010	20488902	Increases in Controls	White Matter	Disease Effects	Huntington's Disease, Normals	15
10060047	2	2010	20488902	Neither	White Matter	Disease Effects	Huntington's Disease, Normals	15
10060048	1	2010	20466498	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	22
10060050	1	2010	20226253	Neither	Gray Matter	Normal Mapping	Normals	55
10060051	1	2010	20483374	Increases in Patients	Gray Matter	Normal Mapping	Normals	19
10060051	2	2010	20483374	Neither	Gray Matter	Normal Mapping	Normals	19
10060052	1	2010	20532166	Increases in Controls	White Matter	Disease Effects	Comitant Extropia, Normals	12
10060052	2	2010	20532166	Increases in Controls	White Matter	Disease Effects	Comitant Extropia, Normals	12
10060052	3	2010	20532166	Increases in Patients	White Matter	Disease Effects	Comitant Extropia, Normals	12
10060053	1	2010	20236763	Increases in Patients	Gray Matter	Disease Effects	Normals, Temporomandibular Disorder	14
10060053	2	2010	20236763	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporomandibular Disorder	14
10060053	3	2010	20236763	Neither	Gray Matter	Disease Effects	Temporomandibular Disorder	14
10060053	4	2010	20236763	Increases in Patients	Gray Matter	Disease Effects	Temporomandibular Disorder	14
10060054	1	2010	20298422	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	13
10060054	2	2010	20298422	Neither	Gray Matter	Disease Effects	Normals, Parkinson's Disease	13
10060054	3	2010	20298422	Neither	Gray Matter	Disease Effects	Normals, Parkinson's Disease	13
10060056	1	2006	16690695	Increases in Patients	Gray Matter	Disease Effects	Normals, Primary Blepharospasm	16
10060056	2	2006	16690695	Increases in Controls	Gray Matter	Disease Effects	Normals, Primary Blepharospasm	16
10060058	1	2005	15709131	Neither	Gray Matter	Age Effects, Normal Mapping	Normals	30
10060058	4	2005	15709131	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	30
10060059	1	2005	15800784	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	30
10060060	1	2005	15866362	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
10060060	2	2005	15866362	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
10060062	1	2006	null	Increases in Controls	Gray Matter	Disease Effects	Schizophrenia	12
10060062	2	2006	null	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	12
10060063	1	2006	16388901	Neither	Gray Matter	Genotype Effects, Age Effects	Normals	41
10060064	1	2006	16514359	Neither	Gray Matter	Disease Effects	Normals, Panic Disorder	10
10060065	1	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	13
10060065	2	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	10
10060065	3	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals	4
10060065	4	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	3
10060065	5	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	4
10060065	6	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	13
10060065	7	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals	4
10060065	8	2010	20483373	Increases in Controls	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	10
10060065	9	2010	20483373	Increases in Controls	Gray Matter	Genotype Effects	Normals, Parkinson's Disease	3
10060065	10	2010	20483373	Increases in Patients	Gray Matter	Genotype Effects	Normals	4
10060066	1	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	2	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	3	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	4	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	5	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	6	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	7	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	8	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	9	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	10	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	11	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	12	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	13	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	14	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	15	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	16	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	17	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	18	2010	20223639	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	30
10060066	19	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060066	20	2010	20223639	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	41
10060067	1	2010	20236343	Increases in Controls	Gray Matter	Disease Effects	Normals, Persistant Idiopathic Facial Pain	11
10060067	2	2010	20236343	Increases in Controls	Gray Matter	Disease Effects	Normals, Persistant Idiopathic Facial Pain	11
10060069	1	2006	16140278	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	10
10060070	1	2010	20478385	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	13
10060070	2	2010	20478385	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	13
10060070	3	2010	20478385	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	11
10060070	4	2010	20478385	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	11
10060070	5	2010	20478385	Neither	Gray Matter	Disease Effects	Schizophrenia	11
10060070	6	2010	20478385	Neither	Gray Matter	Disease Effects	Schizophrenia	11
10060070	7	2010	20478385	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	13
10060070	8	2010	20478385	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	13
10060070	9	2010	20478385	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	11
10060070	10	2010	20478385	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	11
10060070	11	2010	20478385	Neither	White Matter	Disease Effects	Schizophrenia	11
10060070	12	2010	20478385	Neither	White Matter	Disease Effects	Schizophrenia	11
10060071	1	2010	20046492	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	16
10060071	2	2010	20046492	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	16
10060071	3	2010	20046492	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	15
10060071	4	2010	20046492	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	15
10060071	5	2010	20046492	Increases in Controls	White Matter	Disease Effects	Epilepsy, Normals	16
10060071	6	2010	20046492	Increases in Controls	White Matter	Disease Effects	Epilepsy, Normals	16
10060071	7	2010	20046492	Increases in Controls	White Matter	Disease Effects	Epilepsy, Normals	15
10060071	8	2010	20046492	Increases in Controls	White Matter	Disease Effects	Epilepsy, Normals	15
10060072	1	2010	20538022	Neither	Gray Matter	Normal Mapping	Normals	21
10060073	1	2010	20220122	Increases in Controls	Gray Matter	Disease Effects	Myotonic Dystrophy, Normals	14
10060073	2	2010	20220122	Increases in Controls	Gray Matter	Disease Effects	Myotonic Dystrophy, Normals	9
11020002	1	2009	19770474	Neither	Gray Matter	Disease Effects	Posttraumatic Headache	12
11020002	2	2009	19770474	Neither	Gray Matter	Disease Effects	Posttraumatic Headache	12
11020003	1	2009	19073757	Increases in Controls	Gray Matter	Disease Effects	Normals, Pain Disorder	14
11020003	2	2009	19073757	Neither	Gray Matter	Disease Effects	Pain Disorder	14
11020003	3	2009	19073757	Neither	Gray Matter	Disease Effects	Pain Disorder	14
11020004	1	2010	20518076	Increases in Controls	Gray Matter	Disease Effects	Normals, Osteoarthritis	16
11020004	2	2010	20518076	Increases in Patients	Gray Matter	Disease Effects	Normals, Osteoarthritis	16
11020004	3	2010	20518076	Increases in Patients	Gray Matter	Disease Effects, Treatment Effects	Normals, Osteoarthritis	16
11020004	4	2010	20518076	Neither	Gray Matter	Disease Effects	Osteoarthritis	16
11020004	5	2010	20518076	Increases in Controls	Gray Matter	Disease Effects, Treatment Effects	Normals, Osteoarthritis	16
11020004	6	2010	20518076	Increases in Patients	Gray Matter	Disease Effects, Treatment Effects	Normals, Osteoarthritis	16
11020004	7	2010	20518076	Increases in Patients	Gray Matter	Disease Effects, Treatment Effects	Normals, Osteoarthritis	16
11030005	1	2008	17986275	Increases in Controls	Gray Matter	Disease Effects	Migraines, Normals	31
11030006	1	2005	16275843	Increases in Controls	Gray Matter	Disease Effects	Chronic Tension Type Headache, Normals	20
11030007	1	2008	18930351	Increases in Patients	Gray Matter	Disease Effects	Normals, Provoked Vestibulodynia (PVD)	14
11030008	1	2010	20705214	Increases in Patients	Gray Matter	Disease Effects	Normals, Primary Dysmenorrhea	32
11030008	2	2010	20705214	Increases in Controls	Gray Matter	Disease Effects	Normals, Primary Dysmenorrhea	32
11030008	3	2010	20705214	Neither	Gray Matter	Disease Effects	Primary Dysmenorrhea	32
11030008	4	2010	20705214	Neither	Gray Matter	Disease Effects	Primary Dysmenorrhea	32
11030008	5	2010	20705214	Neither	Gray Matter	Disease Effects	Primary Dysmenorrhea	32
11030008	6	2010	20705214	Neither	Gray Matter	Disease Effects	Primary Dysmenorrhea	32
11040009	1	2010	19782344	Increases in Controls	Gray Matter	Disease Effects	Insomnia, Normals	13
11040009	2	2010	19782344	Neither	Gray Matter	Disease Effects	Insomnia	24
11040010	1	2007	17632278	Increases in Patients	Gray Matter	Disease Effects	Developmental Stuttering, Normals	26
11040010	2	2007	17632278	Increases in Patients	White Matter	Disease Effects	Developmental Stuttering, Normals	26
11040013	1	2008	18023366	Increases in Controls	Gray Matter	Disease Effects	Developmental Stuttering, Normals	7
11040013	2	2008	18023366	Neither	Gray Matter	Disease Effects	Developmental Stuttering, Normals	7
11040013	3	2008	18023366	Neither	Gray Matter	Disease Effects	Developmental Stuttering, Normals	7
11040015	2	2007	17275340	Neither	Gray Matter	Disease Effects	Postmenopause	48
11040016	1	2010	19679191	Neither	Gray Matter	Age Effects, Normal Mapping	Normals	24
11040016	2	2010	19679191	Neither	White Matter	Age Effects, Normal Mapping	Normals	24
11040017	1	2008	18631978	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	26
11040017	2	2008	18631978	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	21
11040019	3	2008	19015095	Neither	Gray Matter	Normal Mapping, Learning	Normals	20
11040020	1	2009	19645932	Increases in Controls	Gray Matter	Disease Effects	Normals, Unilateral Vestibular Deafferentation	16
11040021	1	2007	17846412	Increases in Controls	Gray Matter	Disease Effects	Idiopathic Downbeat Nystagmus, Normals	11
11040022	1	2010	19770054	Increases in Patients	Gray Matter	Disease Effects	At Risk for Psychosis, Normals	11
11040022	2	2010	19770054	Increases in Controls	Gray Matter	Disease Effects	At Risk for Psychosis, Normals	11
11040025	1	2009	19321314	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
11040025	2	2009	19321314	Increases in Controls	White Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
11040025	3	2009	19321314	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	15
11040025	4	2009	19321314	Increases in Controls	Gray Matter	Disease Effects, Treatment Effects	Normals, Obsessive Compulsive Disorder	15
11040025	5	2009	19321314	Increases in Controls	Gray Matter	Disease Effects, Treatment Effects, Drug Effects	Normals, Obsessive Compulsive Disorder	15
11040025	6	2009	19321314	Increases in Patients	Gray Matter	Disease Effects, Drug Effects, Treatment Effects	Normals, Obsessive Compulsive Disorder	15
11040026	1	2008	18673405	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	16
11040026	2	2008	18673405	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	17
11040026	3	2008	18673405	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	16
11040026	4	2008	18673405	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder, Normals	16
11040028	1	2009	19497005	Neither	Gray Matter	Normal Mapping	Normals	10
11040029	1	2007	17575089	Increases in Patients	Gray Matter	Disease Effects	Type I Diabetes	42
11040029	2	2007	17575089	Neither	Gray Matter	Disease Effects	Type I Diabetes	98
11040029	3	2007	17575089	Neither	Gray Matter	Disease Effects	Type I Diabetes	98
11040029	4	2007	17575089	Neither	White Matter	Disease Effects	Type I Diabetes	98
11040030	1	2009	19846828	Neither	Gray Matter	Age Effects, Disease Effects	Alzheimer's Disease, Normals	33
11040030	2	2009	19846828	Neither	Gray Matter	Age Effects	Alzheimer's Disease, Normals	33
11040030	3	2009	19846828	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	33
11040031	1	2009	19501175	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Normals, Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy (PSP)	4
11040031	2	2009	19501175	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Normals, Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy (PSP)	4
11040033	1	2007	17318550	Neither	Gray Matter	Age Effects	Normals	36
11040034	1	2010	19961939	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Dementia, Normals	4
11040039	1	2010	19683060	Increases in Controls	Gray Matter	Disease Effects	Mesial Temporal Lobe Epilepsy, Normals	34
11040039	2	2010	19683060	Increases in Controls	Gray Matter	Disease Effects	Mesial Temporal Lobe Epilepsy, Normals	23
11040039	3	2010	19683060	Increases in Controls	Gray Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	10
11040039	4	2010	19683060	Increases in Controls	White Matter	Disease Effects	Mesial Temporal Lobe Epilepsy, Normals	34
11040039	5	2010	19683060	Increases in Controls	White Matter	Disease Effects	Mesial Temporal Lobe Epilepsy, Normals	23
11040039	6	2010	19683060	Increases in Controls	White Matter	Disease Effects	Mesial Temporal Lobe Epilepsy, Normals	10
11040039	7	2010	19683060	Neither	White Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	34
11040039	8	2010	19683060	Neither	White Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	23
11040039	9	2010	19683060	Neither	White Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040039	10	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	34
11040039	11	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	23
11040039	12	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040039	13	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	34
11040039	14	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	23
11040039	15	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040039	16	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040039	17	2010	19683060	Neither	Gray Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	10
11040039	18	2010	19683060	Neither	White Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	10
11040039	19	2010	19683060	Neither	White Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040039	20	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040039	21	2010	19683060	Neither	Gray Matter	Disease Effects, Treatment Effects	Mesial Temporal Lobe Epilepsy	10
11040040	1	2009	19560907	Increases in Controls	Gray Matter	Disease Effects	Normals, Panic Disorder	9
11040040	2	2009	19560907	Increases in Patients	Gray Matter	Disease Effects	Panic Disorder	9
11040040	3	2009	19560907	Increases in Patients	Gray Matter	Disease Effects	Panic Disorder	9
11040040	4	2009	19560907	Neither	Gray Matter	Disease Effects	Panic Disorder	15
11040042	1	2008	18669506	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	31
11040042	2	2008	18669506	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	31
11040042	3	2008	18669506	Neither	Gray Matter	Disease Effects	Alzheimer's Disease	31
11040043	1	2010	19660555	Increases in Controls	Gray Matter	Disease Effects	Borderline Personality Disorder, Normals	20
11040043	2	2010	19660555	Increases in Controls	Gray Matter	Disease Effects	Normals, Various Psychiatric Disorders	20
11040044	1	2004	14749292	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	26
11040044	2	2004	14749292	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	26
11040044	3	2004	14749292	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	31
11040044	4	2004	14749292	Increases in Patients	Gray Matter	Disease Effects	Parkinson's Disease	26
11040044	5	2004	14749292	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Parkinson's Disease	26
11040044	6	2004	14749292	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Parkinson's Disease	26
11040045	1	2010	19429131	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	23
11040045	2	2010	19429131	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	23
11040045	3	2010	19429131	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder	23
11040045	4	2010	19429131	Neither	Gray Matter	Disease Effects	Bipolar Disorder	23
11040046	1	2008	18669483	Increases in Patients	Gray Matter	Disease Effects	Schizophrenia	16
11040046	2	2008	18669483	Increases in Controls	Gray Matter	Normal Mapping	Normals	11
11040047	1	2009	19233148	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	10
11040047	2	2009	19233148	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	10
11040048	1	2008	18520994	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
11040048	2	2008	18520994	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
11040048	3	2008	18520994	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
11040049	1	2009	19726644	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	30
11040050	1	2009	18624787	Increases in Controls	Gray Matter	Disease Effects	Narcolepsy, Normals	17
11040051	1	2009	19666084	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	14
11040052	1	2009	19704079	Increases in Controls	Gray Matter	Disease Effects	Normals, Unverricht-Lundborg Disease	30
11040053	1	2010	19375076	Increases in Patients	Gray Matter	Disease Effects	Developmental Stuttering, Normals	12
11040053	2	2010	19375076	Increases in Controls	Gray Matter	Disease Effects	Developmental Stuttering, Normals	12
11040053	3	2010	19375076	Increases in Patients	White Matter	Disease Effects	Developmental Stuttering, Normals	12
11040053	4	2010	19375076	Increases in Controls	White Matter	Disease Effects	Developmental Stuttering, Normals	12
11040055	1	2009	19356262	Increases in Patients	White Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	18
11040055	2	2009	19356262	Increases in Patients	White Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	18
11040055	3	2009	19356262	Increases in Controls	White Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	18
11040055	4	2009	19356262	Increases in Patients	White Matter	Disease Effects	Asperger's Syndrome, Normals	18
11040055	5	2009	19356262	Increases in Controls	White Matter	Disease Effects	Asperger's Syndrome, Normals	18
11040057	1	2008	19224318	Increases in Controls	Gray Matter	Disease Effects	Myotonic Dystrophy, Normals	13
11040057	2	2008	19224318	Increases in Controls	White Matter	Disease Effects	Myotonic Dystrophy, Normals	13
11040058	1	2008	18056158	Increases in Controls	Gray Matter	Disease Effects	Normals, Preterm Birth	34
11040058	2	2008	18056158	Increases in Patients	Gray Matter	Disease Effects	Normals, Preterm Birth	34
11040058	3	2008	18056158	Increases in Controls	White Matter	Disease Effects	Normals, Preterm Birth	34
11040058	4	2008	18056158	Increases in Patients	White Matter	Normal Mapping	Normals, Preterm Birth	34
11040059	2	2008	19727332	Neither	Gray Matter	Disease Effects	Dementia	8
11040060	1	2009	19412935	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	20
11040060	2	2009	19412935	Neither	Gray Matter	Disease Effects	Parkinson's Disease	36
11040060	3	2009	19412935	Neither	Gray Matter	Disease Effects	Parkinson's Disease	36
11040061	1	2008	18407470	Neither	Gray Matter	Drug Effects	Normals	211
11040061	2	2008	18407470	Neither	White Matter	Drug Effects	Normals	211
11040063	1	2009	19717283	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
11040063	2	2009	19717283	Neither	Gray Matter	Disease Effects	Normals, Schizophrenia	25
11040063	3	2009	19717283	Neither	Gray Matter	Disease Effects	Schizophrenia	25
11040063	4	2009	19717283	Neither	Gray Matter	Disease Effects	Normals	45
11040064	1	2010	19187475	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	11
11040064	2	2010	19187475	Increases in Controls	White Matter	Disease Effects	Multiple-System Atrophy, Normals	11
11040065	4	2009	19464376	Neither	Gray Matter	Disease Effects	Neurocardiogenic Syncope	18
11040065	5	2009	19464376	Neither	Gray Matter	Disease Effects	Neurocardiogenic Syncope	18
11040065	6	2009	19464376	Neither	Gray Matter	Disease Effects	Neurocardiogenic Syncope	18
11040065	7	2009	19464376	Neither	Gray Matter	Disease Effects	Neurocardiogenic Syncope	18
11040065	8	2009	19464376	Neither	Gray Matter	Disease Effects	Neurocardiogenic Syncope	18
11040066	1	2008	18541800	Increases in Controls	Gray Matter	Disease Effects	Corticobasal Degeneration, Normals	20
11040068	1	2008	18539438	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	30
11040068	2	2008	18539438	Neither	Gray Matter	Disease Effects	Schizophrenia	52
11040068	3	2008	18539438	Neither	Gray Matter	Disease Effects	Schizophrenia	52
11040068	4	2008	18539438	Neither	Gray Matter	Disease Effects	Schizophrenia	52
11040069	1	2010	19794403	Neither	Gray Matter	Genotype Effects	Schizophrenia	18
11040070	1	2009	19775870	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	19
11040070	2	2009	19775870	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	19
11040071	1	2010	20063353	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	12
11040072	1	2004	15664796	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	35
11040072	2	2004	15664796	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	35
11040072	3	2004	15664796	Neither	Gray Matter	Disease Effects	Schizophrenia	35
11040073	1	2009	19491709	Increases in Controls	White Matter	Disease Effects	Deaf, Normals	13
11040074	1	2010	19780790	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	19
11040074	2	2010	19780790	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	19
11040075	2	2009	19622691	Neither	Gray Matter	Normal Mapping	Normals	30
11040077	1	2010	19729041	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	15
11040079	1	2008	18765649	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	14
11040079	2	2008	18765649	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	14
11040079	3	2008	18765649	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	14
11040079	4	2008	18765649	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	14
11040079	5	2008	18765649	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	14
11040080	1	2010	19959342	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	21
11040082	1	2009	18608980	Increases in Controls	Gray Matter	Age Effects	Normals	10
11040083	1	2008	18588593	Increases in Controls	Unknown	Disease Effects	Normals, Panic Disorder	26
11040084	1	2010	20553879	Increases in Controls	Gray Matter	Disease Effects	Hyposmia, Normals	24
11040084	2	2010	20553879	Increases in Controls	White Matter	Disease Effects	Hyposmia, Normals	24
11040084	3	2010	20553879	Increases in Controls	Gray Matter	Disease Effects	Hyposmia, Normals	17
11040085	1	2008	18362056	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
11040085	2	2008	18362056	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
11040087	1	2008	18501636	Increases in Patients	Gray Matter	Disease Effects	Clinically Isolated Syndrome, Multiple Sclerosis	26
11040087	2	2008	18501636	Increases in Patients	Gray Matter	Disease Effects	Multiple Sclerosis	26
11040087	3	2008	18501636	Increases in Patients	Gray Matter	Disease Effects	Multiple Sclerosis	18
11040088	1	2009	19752449	Neither	Gray Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	20
11040088	2	2009	19752449	Neither	White Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	20
11040088	3	2009	19752449	Neither	Gray Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	13
11040088	4	2009	19752449	Neither	White Matter	Disease Effects	Mesial Temporal Lobe Epilepsy	13
11040089	3	2009	19293245	Increases in Patients	Gray Matter	Normal Mapping	Normals	23
11040089	4	2009	19293245	Increases in Patients	Gray Matter	Normal Mapping	Normals	23
11040089	5	2009	19293245	Increases in Patients	Gray Matter	Normal Mapping	Normals	23
11040089	6	2009	19293245	Increases in Patients	Gray Matter	Normal Mapping	Normals	23
11040090	2	2008	18603414	Neither	Gray Matter	Disease Effects	Schizoaffective Disorder, Schizophrenia	17
11040090	3	2008	18603414	Neither	Gray Matter	Disease Effects	Schizoaffective Disorder, Schizophrenia	17
11040091	7	2009	19887506	Increases in Controls	Gray Matter	Disease Effects	Normals, Prosopagnosia	17
11040091	8	2009	19887506	Increases in Patients	Gray Matter	Disease Effects	Normals, Prosopagnosia	17
11040091	9	2009	19887506	Increases in Controls	Gray Matter	Disease Effects	Normals, Prosopagnosia	17
11040091	10	2009	19887506	Increases in Patients	Gray Matter	Disease Effects	Normals, Prosopagnosia	17
11040092	2	2007	18418472	Neither	Gray Matter	Normal Mapping	Normals	44
11040093	1	2006	16198126	Neither	Gray Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	2	2006	16198126	Neither	Gray Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	3	2006	16198126	Neither	White Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	4	2006	16198126	Neither	White Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	5	2006	16198126	Neither	Gray Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	6	2006	16198126	Neither	Gray Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	7	2006	16198126	Neither	White Matter	Handedness Effects, Normal Mapping	Normals	56
11040093	8	2006	16198126	Neither	White Matter	Handedness Effects, Normal Mapping	Normals	56
11040094	1	2008	18356764	Increases in Controls	Gray Matter	Disease Effects	Conduct Disorder, Normals	23
11040094	2	2008	18356764	Increases in Patients	Gray Matter	Disease Effects	Conduct Disorder, Normals	23
11040094	3	2008	18356764	Neither	Gray Matter	Disease Effects	Conduct Disorder	23
11040094	4	2008	18356764	Neither	Gray Matter	Disease Effects	Conduct Disorder	23
11040095	1	2008	18417700	Neither	Gray Matter	Learning, Normal Mapping	Normals	18
11040096	1	2008	18346506	Increases in Controls	Gray Matter	Disease Effects	Normals, Preterm Birth	10
11040096	2	2008	18346506	Increases in Controls	White Matter	Disease Effects	Normals, Preterm Birth	10
11040096	4	2008	18346506	Increases in Controls	Gray Matter	Disease Effects	Normals, Preterm Birth	10
11040096	5	2008	18346506	Increases in Controls	Gray Matter	Disease Effects	Normals, Preterm Birth	10
11040097	1	2009	19292997	Neither	Gray Matter	Normal Mapping	Normals	20
11040097	2	2009	19292997	Neither	Gray Matter	Normal Mapping	Normals	20
11040098	3	2009	19399879	Increases in Patients	Gray Matter	Disease Effects	Mild Cognitive Impairment	26
11040098	4	2009	19399879	Increases in Patients	Gray Matter	Disease Effects	Mild Cognitive Impairment	26
11040099	1	2007	18166607	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	11
11040099	2	2007	18166607	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	18
11040099	3	2007	18166607	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration, Normals	11
11040099	4	2007	18166607	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration	11
11040099	5	2007	18166607	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Frontotemporal Lobar Degeneration	11
11040101	1	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	2	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	3	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	4	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	5	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	6	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	7	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	8	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	9	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	10	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	11	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	12	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040101	13	2009	19540253	Neither	Gray Matter	Disease Effects	Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Normals, Progressive Supranuclear Palsy (PSP)	6
11040102	1	2009	19948618	Increases in Controls	Gray Matter	Disease Effects	Normals, Preterm Birth	20
11040102	2	2009	19948618	Increases in Controls	White Matter	Disease Effects	Normals, Preterm Birth	20
11040102	3	2009	19948618	Neither	Gray Matter	Disease Effects	Normals, Preterm Birth	20
11040102	4	2009	19948618	Neither	White Matter	Disease Effects	Normals, Preterm Birth	20
11040103	2	2008	18413702	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	26
11040103	3	2008	18413702	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	26
11040104	1	2008	18582579	Neither	Gray Matter	Normal Mapping, Treatment Effects	Normals	14
11040106	1	2009	19250174	Increases in Controls	Gray Matter	Disease Effects	Normals, Obstructive Sleep Apnea	14
11040107	1	2008	18165464	Increases in Controls	Gray Matter	Drug Effects, Normal Mapping	Normals, Smokers	39
11040108	1	2010	20108225	Neither	White Matter	Disease Effects	Multiple Sclerosis	45
11040110	1	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040110	2	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040110	3	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040110	4	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040110	5	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040110	6	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040110	7	2010	20127871	Neither	Gray Matter	Normal Mapping	Normals	32
11040111	1	2008	18164594	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	13
11040112	1	2008	18789654	Neither	Gray Matter	Disease Effects	Psychosis	10
11040113	1	2009	19221425	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	8
11040113	2	2009	19221425	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	8
11040113	3	2009	19221425	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	8
11040113	4	2009	19221425	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	8
11040114	1	2010	19768657	Increases in Patients	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	17
11040114	2	2010	19768657	Increases in Controls	Gray Matter	Disease Effects	Normals, Restless Legs Syndrome	17
11040115	1	2009	19521637	Neither	Gray Matter	Disease Effects	Schizophrenia	90
11040116	1	2009	19486137	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	10
11040116	2	2009	19486137	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	10
11040116	3	2009	19486137	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	13
11040117	1	2008	18672073	Increases in Controls	Gray Matter	Disease Effects	Normals, Spinocerebellar Ataxia	10
11040117	2	2008	18672073	Increases in Controls	White Matter	Disease Effects	Normals, Spinocerebellar Ataxia	10
11040117	3	2008	18672073	Increases in Controls	Gray Matter	Disease Effects	Normals, Spinocerebellar Ataxia	10
11040117	4	2008	18672073	Increases in Controls	White Matter	Disease Effects	Normals, Spinocerebellar Ataxia	10
11040118	1	2009	19280106	Increases in Controls	White Matter	Disease Effects	Ataxia, Normals	24
11040119	1	2010	19879920	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	13
11040119	2	2010	19879920	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	13
11040120	1	2009	18672026	Increases in Patients	Gray Matter	Normal Mapping, Learning	Normals	18
11040120	2	2009	18672026	Increases in Controls	Gray Matter	Normal Mapping, Learning	Normals	18
11040122	1	2009	19266143	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	20
11040122	2	2009	19266143	Increases in Patients	Gray Matter	Disease Effects	Huntington's Disease	21
11040122	3	2009	19266143	Neither	Gray Matter	Disease Effects	Huntington's Disease	21
11040123	1	2009	19812458	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	56
11040123	2	2009	19812458	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	56
11040123	3	2009	19812458	Neither	White Matter	Disease Effects	Alzheimer's Disease	60
11040124	1	2009	19182174	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	13
11040124	2	2009	19182174	Neither	Gray Matter	Disease Effects	Schizophrenia	13
11040125	1	2009	19822784	Increases in Controls	Gray Matter	Disease Effects	Corticobasal Syndrome, Normals	14
11040125	2	2009	19822784	Neither	Gray Matter	Disease Effects	Corticobasal Syndrome	48
11040127	1	2010	20175407	Increases in Controls	Gray Matter	Disease Effects	Normals, Obstructive Sleep Apnea	31
11040128	1	2009	19784372	Neither	Unknown	Normal Mapping	Normals	40
11040128	2	2009	19784372	Neither	Unknown	Normal Mapping	Normals	40
11040128	3	2009	19784372	Neither	Unknown	Normal Mapping	Normals	40
11040129	1	2009	19625009	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	26
11040129	2	2009	19625009	Neither	Gray Matter	Disease Effects	Schizophrenia	26
11040130	1	2008	18761134	Neither	Gray Matter	Disease Effects	Schizophrenia	42
11040131	1	2009	19280691	Neither	Gray Matter	Normal Mapping	Normals	22
11040131	2	2009	19280691	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	22
11040132	1	2010	19747928	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Corticobasal Degeneration, Frontotemporal Dementia, Mild Cognitive Impairment, Normals, Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy (PSP), Semantic Dementia	2
11040132	2	2010	19747928	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Corticobasal Degeneration, Frontotemporal Dementia, Mild Cognitive Impairment, Normals, Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy (PSP), Semantic Dementia	2
11040133	1	2009	19596037	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	17
11040133	2	2009	19596037	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	17
11040135	1	2007	18090419	Increases in Patients	Gray Matter	Disease Effects	Progressive Nonfluent Aphasia	7
11040137	1	2009	19666833	Neither	White Matter	Disease Effects	Schizophrenia	12
11040138	1	2010	20065955	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	31
11040138	2	2010	20065955	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	31
11040139	1	2009	19402921	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Mild Cognitive Impairment, Normals	3
11040139	2	2009	19402921	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Mild Cognitive Impairment, Normals	3
11040140	1	2010	20028706	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	35
11040140	2	2010	20028706	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	128
11040140	3	2010	20028706	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	128
11040141	1	2010	20016963	Increases in Controls	Gray Matter	Disease Effects	Normals, Spinocerebellar Ataxia	9
11040141	2	2010	20016963	Neither	Gray Matter	Disease Effects	Spinocerebellar Ataxia	9
11040141	3	2010	20016963	Neither	Gray Matter	Disease Effects	Spinocerebellar Ataxia	9
11040141	4	2010	20016963	Neither	Gray Matter	Disease Effects	Spinocerebellar Ataxia	9
11040141	5	2010	20016963	Neither	Gray Matter	Disease Effects	Spinocerebellar Ataxia	9
11040141	6	2010	20016963	Neither	Gray Matter	Disease Effects	Spinocerebellar Ataxia	9
11040141	7	2010	20016963	Neither	Gray Matter	Disease Effects	Spinocerebellar Ataxia	9
11040142	1	2009	19463699	Neither	Gray Matter	Normal Mapping	Normals	47
11040142	2	2009	19463699	Neither	Gray Matter	Normal Mapping	Normals	47
11040145	1	2010	20056020	Increases in Controls	Gray Matter	Disease Effects	Normals, Panic Disorder	17
11040146	1	2008	18765280	Increases in Controls	White Matter	Disease Effects	Preterm Birth	44
11040146	2	2008	18765280	Neither	White Matter	Disease Effects	Preterm Birth	44
11040147	1	2009	19267696	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	66
11040147	2	2009	19267696	Increases in Controls	White Matter	Disease Effects	Bipolar Disorder, Normals	66
11040147	5	2009	19267696	Neither	Gray Matter	Age Effects	Bipolar Disorder, Normals	66
11040148	1	2008	18258824	Increases in Controls	Gray Matter	Disease Effects	Stroke	40
11040149	1	2009	19494444	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	27
11040150	1	2009	19194988	Increases in Patients	Gray Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	14
11040150	2	2009	19194988	Increases in Patients	Gray Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	14
11040150	3	2009	19194988	Increases in Controls	Gray Matter	Disease Effects	Multiple-System Atrophy, Normals	14
11040150	4	2009	19194988	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	14
11040151	1	2009	19446957	Increases in Controls	Gray Matter	Disease Effects	Herpes Simplex Virus, Normals	8
11040152	1	2009	19853418	Increases in Patients	Gray Matter	Genotype Effects, Disease Effects	Autism Spectrum Disorder, Fragile X Syndrome	10
11040152	2	2009	19853418	Increases in Patients	Gray Matter	Genotype Effects, Disease Effects	Autism Spectrum Disorder, Fragile X Syndrome	10
11040152	4	2009	19853418	Increases in Patients	Gray Matter	Genotype Effects, Disease Effects	Fragile X Syndrome, Normals	10
11040152	8	2009	19853418	Neither	Gray Matter	Genotype Effects, Disease Effects	Autism Spectrum Disorder, Fragile X Syndrome, Normals	10
11040152	9	2009	19853418	Increases in Patients	Gray Matter	Genotype Effects, Disease Effects	Autism Spectrum Disorder, Fragile X Syndrome	10
11040152	10	2009	19853418	Increases in Patients	Gray Matter	Genotype Effects, Disease Effects	Autism Spectrum Disorder, Fragile X Syndrome, Normals	10
11040153	1	2010	20350980	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	40
11040153	2	2010	20350980	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	29
11040153	3	2010	20350980	Increases in Patients	Gray Matter	Disease Effects, Genotype Effects	Temporal Lobe Epilepsy	29
11040153	4	2010	20350980	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	40
11040153	5	2010	20350980	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	29
11040155	2	2010	20175674	Neither	Gray Matter	Normal Mapping	Normals	58
11040156	2	2010	20439317	Neither	Gray Matter	Normal Mapping	Normals	91
11040158	1	2008	18191160	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	12
11040158	2	2008	18191160	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	12
11040158	3	2008	18191160	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	16
11040158	4	2008	18191160	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	12
11040158	5	2008	18191160	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	12
11040158	6	2008	18191160	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	12
11040158	7	2008	18191160	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	12
11040159	1	2009	19172648	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	23
11040160	1	2008	18195263	Increases in Controls	Gray Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
11040160	2	2008	18195263	Increases in Controls	White Matter	Disease Effects	Normals, Temporal Lobe Epilepsy	12
11040162	1	2008	18717724	Increases in Controls	White Matter	Normal Mapping	Normals	9
11040162	2	2008	18717724	Neither	Gray Matter	Normal Mapping	Normals	9
11040163	1	2008	18945600	Increases in Controls	Gray Matter	Disease Effects	Normals, Posterior Cortical Atrophy	1
11040163	2	2008	18945600	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	6
11040164	1	2008	18784377	Increases in Patients	Unknown	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	16
11040164	2	2008	18784377	Neither	Unknown	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	26
11040164	3	2008	18784377	Neither	Unknown	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	26
11040165	1	2008	18762595	Increases in Patients	Gray Matter	Genotype Effects, Disease Effects	Fragile X Syndrome, Idiopathic Developmental Delay, Normals	18
11040165	2	2008	18762595	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Fragile X Syndrome, Idiopathic Developmental Delay, Normals	18
11040165	3	2008	18762595	Increases in Patients	White Matter	Genotype Effects, Disease Effects	Fragile X Syndrome, Idiopathic Developmental Delay, Normals	18
11040165	4	2008	18762595	Increases in Controls	White Matter	Genotype Effects, Disease Effects	Fragile X Syndrome, Idiopathic Developmental Delay, Normals	18
11040166	1	2009	19721112	Neither	Gray Matter	Disease Effects	Psychosis	70
11040166	2	2009	19721112	Neither	Gray Matter	Disease Effects	Psychosis	70
11040168	1	2008	18930633	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	22
11040169	1	2009	19570650	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	17
11040169	2	2009	19570650	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	17
11040169	3	2009	19570650	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	17
11040169	4	2009	19570650	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	30
11040169	5	2009	19570650	Neither	Gray Matter	Disease Effects	Epilepsy	17
11040169	6	2009	19570650	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	17
11040169	7	2009	19570650	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	30
11040170	1	2009	19683418	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	11
11040170	2	2009	19683418	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	11
11040170	3	2009	19683418	Neither	Gray Matter	Disease Effects	Schizophrenia	15
11040173	1	2009	19267168	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	12
11040173	2	2009	19267168	Neither	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	12
11040174	1	2009	19335934	Neither	Gray Matter	Genotype Effects	Normals	33
11040175	1	2009	19139305	Increases in Controls	Gray Matter	Disease Effects	Corticobasal Syndrome, Normals	12
11040175	2	2009	19139305	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	12
11040176	1	2009	19349926	Neither	Gray Matter	Disease Effects	Parkinson's Disease	32
11040177	1	2009	19628025	Neither	Gray Matter	Normal Mapping	Normals	12
11040177	2	2009	19628025	Neither	Gray Matter	Normal Mapping	Normals	12
11040179	1	2008	19008082	Neither	White Matter	Disease Effects	Schizophrenia	10
11040179	2	2008	19008082	Neither	White Matter	Disease Effects	Schizophrenia	10
11040181	1	2010	20174515	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	27
11040182	2	2009	19172640	Neither	Gray Matter	Disease Effects	Borderline Personality Disorder, Normals	6
11040183	2	2008	19013775	Neither	Gray Matter	Gender Effects	Attention Deficit/Hyperactivity Disorder, Normals	22
11040183	3	2008	19013775	Neither	Gray Matter	Disease Effects, Gender Effects	Attention Deficit/Hyperactivity Disorder, Normals	22
11040184	3	2008	18303194	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	24
11040184	4	2008	18303194	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	24
11040184	5	2008	18303194	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	24
11040184	6	2008	18303194	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	24
11040184	7	2008	18303194	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	24
11040184	8	2008	18303194	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	47
11040184	9	2008	18303194	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	47
11040184	10	2008	18303194	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	24
11040184	11	2008	18303194	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	24
11040184	12	2008	18303194	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	24
11040184	13	2008	18303194	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	24
11040184	14	2008	18303194	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	24
11040185	3	2008	18289882	Increases in Controls	Gray Matter	Disease Effects	Antisocial Personality Disorder, Normals	15
11040186	1	2009	18952675	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	50
11040186	2	2009	18952675	Increases in Controls	White Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	50
11040186	3	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	4	2009	18952675	Increases in Controls	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	5	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	6	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	7	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	8	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	9	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	10	2009	18952675	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	11	2009	18952675	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	12	2009	18952675	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	13	2009	18952675	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	14	2009	18952675	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	15	2009	18952675	Neither	White Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040186	16	2009	18952675	Neither	Gray Matter	Disease Effects	Obsessive Compulsive Disorder	55
11040187	1	2009	18854439	Increases in Controls	Gray Matter	Disease Effects	Normals, Subacute Sclerosing Panencephalitis	17
11040188	1	2010	20167205	Neither	Gray Matter	Drug Effects, Disease Effects	Multiple Sclerosis	15
11040188	2	2010	20167205	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	50
11040188	3	2010	20167205	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Multiple Sclerosis	15
11040189	1	2009	19707568	Increases in Controls	Gray Matter	Disease Effects	Alcoholism, Normals	24
11040190	1	2009	19538748	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	12
11040191	1	2009	19409211	Increases in Controls	Gray Matter	Disease Effects	Cerebellar Damage, Normals	8
11040191	2	2009	19409211	Neither	Gray Matter	Disease Effects	Cerebellar Damage	8
11040193	1	2010	20211265	Neither	Gray Matter	Age Effects	Normals	10
11040193	2	2010	20211265	Neither	White Matter	Age Effects	Normals	10
11040193	3	2010	20211265	Neither	White Matter	Age Effects	Normals	10
11040194	1	2007	17933587	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	14
11040194	2	2007	17933587	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	14
11040194	3	2007	17933587	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	14
11040194	4	2007	17933587	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	14
11040194	5	2007	17933587	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	14
11040194	6	2007	17933587	Neither	Gray Matter	Disease Effects	Temporal Lobe Epilepsy	14
11040196	1	2010	19790171	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	13
11040196	2	2010	19790171	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	13
11040196	3	2010	19790171	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	13
11040198	1	2009	19531112	Increases in Controls	Gray Matter	Drug Effects	Heroin-Dependent, Normals	15
11040199	1	2009	19531975	Increases in Patients	Gray Matter	Disease Effects	Mental Retardation, Normals	26
11040199	2	2009	19531975	Increases in Controls	Gray Matter	Disease Effects	Mental Retardation, Normals	26
11040199	3	2009	19531975	Increases in Patients	White Matter	Disease Effects	Mental Retardation, Normals	26
11040199	4	2009	19531975	Increases in Controls	White Matter	Disease Effects	Mental Retardation, Normals	26
11040200	1	2009	19158440	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	9
11040200	2	2009	19158440	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	5
11040200	3	2009	19158440	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	9
11040200	4	2009	19158440	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	5
11040201	1	2009	19435502	Increases in Controls	Gray Matter	Disease Effects	Normals, Tourette Syndrome	19
11040201	2	2009	19435502	Increases in Controls	White Matter	Disease Effects	Normals, Tourette Syndrome	19
11040201	3	2009	19435502	Increases in Controls	White Matter	Disease Effects	Normals, Tourette Syndrome	19
11040201	4	2009	19435502	Neither	Gray Matter	Disease Effects	Tourette Syndrome	19
11040203	1	2007	17560797	Increases in Controls	Gray Matter	Disease Effects	Blindness, Normals	14
11040203	2	2007	17560797	Increases in Controls	White Matter	Disease Effects	Blindness, Normals	14
11040205	1	2009	19442751	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	18
11040205	2	2009	19442751	Increases in Controls	White Matter	Disease Effects	Mild Cognitive Impairment, Normals	18
11040205	3	2009	19442751	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	18
11040205	4	2009	19442751	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	18
11040205	5	2009	19442751	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	18
11040206	1	2009	19929215	Neither	Gray Matter	Disease Effects	Traumatic Brain Injury	11
11040206	2	2009	19929215	Neither	White Matter	Disease Effects	Traumatic Brain Injury	11
11040207	1	2010	20007429	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	10
11040208	1	2009	19536354	Neither	Gray Matter	Age Effects, Normal Mapping	Normals	15
11040210	1	2009	19285558	Increases in Controls	Gray Matter	Normal Mapping	Normals	22
11040211	1	2010	20463111	Increases in Controls	White Matter	Disease Effects	Normals, Traumatic Brain Injury	14
11040211	2	2010	20463111	Increases in Controls	Gray Matter	Disease Effects	Normals, Traumatic Brain Injury	14
11040212	1	2009	19444953	Neither	White Matter	Drug Effects	Alzheimer's Disease	9
11040212	2	2009	19444953	Neither	White Matter	Drug Effects	Alzheimer's Disease	8
11040212	3	2009	19444953	Neither	White Matter	Drug Effects	Alzheimer's Disease	9
11040212	4	2009	19444953	Neither	White Matter	Drug Effects	Alzheimer's Disease	8
11040213	1	2010	19443157	Increases in Controls	White Matter	Disease Effects	Mild Cognitive Impairment, Normals	14
11040214	1	2009	19786698	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Frontotemporal Dementia, Normals	4
11040214	2	2009	19786698	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Normals, Various Neurodegenerative Diseases	3
11040214	3	2009	19786698	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Frontotemporal Dementia, Normals	3
11040214	4	2009	19786698	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Frontotemporal Dementia, Normals	2
11040214	5	2009	19786698	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Frontotemporal Dementia, Normals	4
11040214	6	2009	19786698	Increases in Controls	Gray Matter	Genotype Effects, Disease Effects	Frontotemporal Dementia, Normals	3
11040214	7	2009	19786698	Increases in Patients	Gray Matter	Disease Effects, Genotype Effects	Frontotemporal Dementia, Various Neurodegenerative Diseases	2
11040214	8	2009	19786698	Increases in Patients	Gray Matter	Disease Effects, Genotype Effects	Frontotemporal Dementia, Various Neurodegenerative Diseases	2
11040215	1	2007	17934884	Increases in Controls	Gray Matter	Disease Effects	Ataxia, Normals	14
11040215	2	2007	17934884	Increases in Controls	White Matter	Disease Effects	Ataxia, Normals	14
11040215	3	2007	17934884	Neither	Gray Matter	Disease Effects	Ataxia	14
11040216	1	2007	17620785	Increases in Controls	Gray Matter	Normal Mapping	Normals	10
11040216	2	2007	17620785	Increases in Controls	Gray Matter	Normal Mapping	Normals	10
11040217	1	2009	19010397	Increases in Patients	Gray Matter	Gender Effects, Normal Mapping	Normals	25
11040217	2	2009	19010397	Increases in Controls	Gray Matter	Gender Effects, Normal Mapping	Normals	25
11040217	3	2009	19010397	Neither	Gray Matter	Normal Mapping	Normals	25
11040217	4	2009	19010397	Neither	Gray Matter	Normal Mapping	Normals	25
11040217	5	2009	19010397	Neither	Gray Matter	Normal Mapping	Normals	25
11040219	1	2008	18827723	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
11040219	2	2008	18827723	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	20
11040219	3	2008	18827723	Increases in Controls	Gray Matter	Disease Effects	Normals, Psychosis	25
11040220	1	2008	19108660	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Bipolar Disorder	7
11040220	2	2008	19108660	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Bipolar Disorder	7
11040220	3	2008	19108660	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Bipolar Disorder	7
11040221	1	2005	15459079	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	22
11040222	1	2009	19168334	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	10
11040222	2	2009	19168334	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	10
11040222	4	2009	19168334	Increases in Controls	Gray Matter	Genotype Effects, Normal Mapping	Normals	8
11040222	5	2009	19168334	Neither	Gray Matter	Genotype Effects, Normal Mapping	Normals	8
11040223	1	2009	19606493	Increases in Controls	White Matter	Disease Effects	Normals, Parkinson's Disease	14
11040225	1	2010	20113358	Neither	Gray Matter	Genotype Effects	Schizophrenia	6
11040228	1	2010	20452187	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	19
11040228	2	2010	20452187	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	19
11040228	3	2010	20452187	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	31
11040228	4	2010	20452187	Increases in Patients	Gray Matter	Disease Effects	Schizophrenia	19
11040230	1	2009	19026409	Neither	Gray Matter	Normal Mapping	Normals	15
11040231	1	2008	18640784	Neither	White Matter	Genotype Effects, Normal Mapping	Normals	47
11040232	1	2009	19259976	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	14
11040232	2	2009	19259976	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	27
11040232	3	2009	19259976	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	27
11040232	4	2009	19259976	Increases in Patients	Gray Matter	Disease Effects	Mild Cognitive Impairment	14
11040232	5	2009	19259976	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	28
11040233	1	2009	19157420	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	15
11040233	2	2009	19157420	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	15
11040234	1	2009	19270764	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment, Normals	15
11040234	2	2009	19270764	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment, Normals	15
11040234	3	2009	19270764	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	23
11040235	1	2009	19398377	Increases in Controls	Gray Matter	Disease Effects	Fibromyalgia, Normals	20
11050238	1	2009	18781591	Neither	Gray Matter	Disease Effects	Normals	76
11050238	2	2009	18781591	Neither	Gray Matter	Disease Effects	Normals, Sleep-Related Breathing Disorders	25
11050238	3	2009	18781591	Increases in Controls	Gray Matter	Age Effects	Normals, Sleep-Related Breathing Disorders	25
11050239	1	2010	19853041	Neither	Gray Matter	Normal Mapping	Normals	75
11050241	1	2010	19965847	Neither	Gray Matter	Disease Effects	Parkinson's Disease	12
11050241	2	2010	19965847	Neither	Gray Matter	Disease Effects	Parkinson's Disease	14
11050241	3	2010	19965847	Neither	Gray Matter	Disease Effects	Parkinson's Disease	12
11050241	4	2010	19965847	Neither	Gray Matter	Disease Effects	Parkinson's Disease	12
11050241	5	2010	19965847	Neither	Gray Matter	Disease Effects	Parkinson's Disease	12
11050241	6	2010	19965847	Neither	Gray Matter	Disease Effects	Parkinson's Disease	12
11050243	1	2008	18400793	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	6
11050245	1	2007	17892392	Neither	Gray Matter	Normal Mapping	Normals	46
11050245	2	2007	17892392	Neither	Gray Matter	Normal Mapping	Normals	46
11050245	3	2007	17892392	Neither	Gray Matter	Normal Mapping	Normals	46
11050245	6	2007	17892392	Neither	Gray Matter	Normal Mapping	Normals	46
11050249	1	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	2	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	3	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	4	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	5	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	6	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	7	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	8	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	9	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	10	2010	20542982	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Primary Progressive Aphasia, Progressive Nonfluent Aphasia	10
11050249	11	2010	20542982	Neither	Gray Matter	Disease Effects	Primary Progressive Aphasia, Progressive Nonfluent Aphasia	11
11050249	12	2010	20542982	Increases in Controls	Gray Matter	Disease Effects	Primary Progressive Aphasia, Progressive Nonfluent Aphasia	11
11050249	13	2010	20542982	Increases in Controls	Gray Matter	Disease Effects	Primary Progressive Aphasia, Progressive Nonfluent Aphasia	11
11050251	1	2011	20479759	Neither	Gray Matter	Drug Effects	Schizophrenia	16
11050251	2	2011	20479759	Neither	Gray Matter	Age Effects, Drug Effects	Schizophrenia	16
11050251	3	2011	20479759	Neither	Gray Matter	Age Effects, Drug Effects	Schizophrenia	16
11050252	1	2010	19796692	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	29
11050252	2	2010	19796692	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	29
11050252	3	2010	19796692	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	26
11050252	4	2010	19796692	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	26
11050252	5	2010	19796692	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	26
11050252	6	2010	19796692	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	26
11050254	1	2007	17592952	Neither	Gray Matter	Normal Mapping	Normals	64
11050254	2	2007	17592952	Neither	White Matter	Normal Mapping	Normals	64
11050255	1	2010	19942229	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	5
11050255	2	2010	19942229	Increases in Controls	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	5
11050255	3	2010	19942229	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	5
11050256	3	2009	18550597	Neither	Gray Matter	Normal Mapping	Normals	15
11050256	4	2009	18550597	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	15
11050256	5	2009	18550597	Neither	Gray Matter	Normal Mapping	Normals	15
11050256	6	2009	18550597	Neither	Gray Matter	Gender Effects, Normal Mapping	Normals	15
11050256	7	2009	18550597	Neither	Gray Matter	Normal Mapping	Normals	15
11050256	8	2009	18550597	Neither	Gray Matter	Normal Mapping, Gender Effects	Normals	15
11050257	1	2009	19294640	Neither	Gray Matter	Normal Mapping	Normals	195
11050257	2	2009	19294640	Neither	White Matter	Normal Mapping	Normals	195
11050257	3	2009	19294640	Neither	Gray Matter	Normal Mapping	Normals	195
11050258	1	2008	18539046	Increases in Controls	Gray Matter	Disease Effects	Normals, Posterior Fossa Brain Tumor	13
11050258	2	2008	18539046	Increases in Patients	Gray Matter	Disease Effects	Normals, Posterior Fossa Brain Tumor	13
11050258	3	2008	18539046	Increases in Controls	White Matter	Disease Effects	Normals, Posterior Fossa Brain Tumor	13
11050259	1	2007	17327887	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	96
11050259	2	2007	17327887	Increases in Controls	Gray Matter	Disease Effects, Drug Effects	Normals, Schizophrenia	96
11050260	1	2010	20082332	Neither	Gray Matter	Disease Effects	Epilepsy, Normals	20
11050261	1	2009	19901249	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Logopenic Progressive Aphasia, Normals, Posterior Cortical Atrophy	10
11050261	2	2009	19901249	Neither	Gray Matter	Disease Effects	Normals, Posterior Cortical Atrophy	14
11050261	3	2009	19901249	Neither	Gray Matter	Disease Effects	Logopenic Progressive Aphasia, Normals	10
11050261	4	2009	19901249	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	16
11050261	5	2009	19901249	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Logopenic Progressive Aphasia, Normals, Posterior Cortical Atrophy	10
11050261	6	2009	19901249	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Logopenic Progressive Aphasia, Normals, Posterior Cortical Atrophy	10
11050261	7	2009	19901249	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Logopenic Progressive Aphasia, Normals, Posterior Cortical Atrophy	10
11050263	1	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	9
11050263	2	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	6
11050263	3	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	6
11050263	4	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	8
11050263	5	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	4
11050263	6	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	3
11050263	7	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	5
11050263	8	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	3
11050263	9	2009	19433738	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	3
11050264	1	2009	19560122	Neither	Gray Matter	Disease Effects	Childhood Sexual Abuse, Normals	14
11050264	2	2009	19560122	Increases in Controls	Gray Matter	Disease Effects	Childhood Sexual Abuse, Normals	14
11080265	1	2011	21147232	Increases in Controls	Gray Matter	Disease Effects	Normals, Spinocerebellar Ataxia	9
11080268	1	2011	21338692	Increases in Controls	Gray Matter	Drug Effects, Disease Effects	Cocaine-Dependent, Normals	16
11080268	2	2011	21338692	Neither	Gray Matter	Disease Effects, Drug Effects	Cocaine-Dependent	20
11080269	1	2011	21054282	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
11080269	2	2011	21054282	Neither	Unknown	Disease Effects	Schizophrenia	21
11080269	3	2011	21054282	Neither	Unknown	Disease Effects	Schizophrenia	21
11080270	1	2010	20680252	Increases in Controls	Gray Matter	Age Effects, Normal Mapping	Normals	24
11080271	1	2011	21241781	Increases in Controls	Gray Matter	Disease Effects	Normals, Parosmia	22
11080273	1	2006	17014369	Neither	Gray Matter	Disease Effects	Various	152
11080273	2	2006	17014369	Neither	Gray Matter	Disease Effects	Various	152
11080273	3	2006	17014369	Neither	Gray Matter	Disease Effects	Various	152
11080274	1	2007	17766762	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	14
11080274	2	2007	17766762	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	14
11080274	3	2007	17766762	Increases in Patients	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	14
11080275	1	2007	17646630	Increases in Controls	Gray Matter	Disease Effects	Dystonia, Normals	30
11080276	1	2007	17698497	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
11080277	1	2007	17588241	Increases in Patients	Gray Matter	Disease Effects	Cervical Dystonia, Dystonia, Focal Hand Dystonia, Normals	9
11080277	2	2007	17588241	Increases in Patients	Gray Matter	Disease Effects	Dystonia, Normals	9
11080277	3	2007	17588241	Increases in Patients	Gray Matter	Disease Effects	Focal Hand Dystonia, Normals	11
11080278	1	2007	17951002	Increases in Controls	Gray Matter	Disease Effects, Drug Effects	Alcoholism, Normals	20
11080278	2	2007	17951002	Increases in Controls	White Matter	Disease Effects, Drug Effects	Alcoholism, Normals	20
11080279	3	2007	17579363	Neither	Gray Matter	Disease Effects	Huntington's Disease	33
11080279	4	2007	17579363	Neither	White Matter	Disease Effects	Huntington's Disease	33
11080280	1	2007	17332050	Increases in Controls	Gray Matter	Disease Effects	Kennedy's Disease, Normals	18
11080280	2	2007	17332050	Increases in Controls	White Matter	Disease Effects	Kennedy's Disease, Normals	18
11080281	1	2007	17689105	Increases in Controls	Gray Matter	Disease Effects	Juvenile Myoclonic Epilepsy, Normals	25
11080281	2	2007	17689105	Increases in Patients	Gray Matter	Disease Effects	Juvenile Myoclonic Epilepsy, Normals	25
11080282	1	2007	17603086	Neither	Gray Matter	Normal Mapping	Normals	20
11080284	1	2011	20478698	Increases in Patients	Gray Matter	Disease Effects, Genotype Effects	Multiple Sclerosis	59
11080286	1	2010	20725527	Neither	Gray Matter	Normal Mapping	Normals	183
11080287	1	2007	17224120	Increases in Controls	Gray Matter	Disease Effects	Amblyopia, Normals	13
11080288	1	2011	20809128	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	18
11080288	2	2011	20809128	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	18
11080288	3	2011	20809128	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	18
11080289	1	2011	21108975	Increases in Patients	Gray Matter	Genotype Effects	Alzheimer's Disease, Normals	9
11080289	2	2011	21108975	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	9
11080290	1	2011	20699124	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Normals, Smokers	48
11080291	1	2011	20807579	Neither	Gray Matter	Normal Mapping	Normals	55
11080292	1	2006	16450382	Increases in Controls	White Matter	Disease Effects	Normals, Sickle Cell Disease	16
11080292	2	2006	16450382	Increases in Controls	White Matter	Disease Effects	Normals, Sickle Cell Disease	20
11080292	3	2006	16450382	Increases in Controls	Gray Matter	Disease Effects	Normals, Sickle Cell Disease	16
11080292	4	2006	16450382	Increases in Controls	Gray Matter	Disease Effects	Normals, Sickle Cell Disease	20
11080293	1	2007	17098398	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	26
11080293	2	2007	17098398	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	26
11080293	3	2007	17098398	Increases in Patients	CSI	Disease Effects	Normals, Schizophrenia	26
11080294	2	2006	16894060	Neither	Gray Matter	Disease Effects, Genotype Effects	Schizophrenia	13
11080295	1	2008	17636558	Increases in Patients	Gray Matter	Disease Effects	Dyslexia, Normals	13
11080295	2	2008	17636558	Increases in Controls	Gray Matter	Disease Effects	Dyslexia, Normals	13
11080295	3	2008	17636558	Increases in Patients	Gray Matter	Disease Effects	Dyslexia, Normals	13
11080296	6	2011	20964952	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	30
11080296	11	2011	20964952	Neither	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	30
11080296	12	2011	20964952	Increases in Controls	White Matter	Disease Effects	Normals	17
11080297	1	2010	21074899	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	24
11080297	2	2010	21074899	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	18
11080297	3	2010	21074899	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Alzheimer's Disease, Normals	3
11080297	4	2010	21074899	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Normals	12
11080297	5	2010	21074899	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Normals	2
11080297	6	2010	21074899	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Normals	9
11080297	7	2010	21074899	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	24
11080297	8	2010	21074899	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	18
11080299	1	2011	21508220	Increases in Controls	Gray Matter	Disease Effects	Normals, Trigeminal Neuropathic Pain	21
11080299	2	2011	21508220	Increases in Patients	Gray Matter	Disease Effects	Normals, Trigeminal Neuropathic Pain	21
11080299	3	2011	21508220	Increases in Patients	Gray Matter	Disease Effects	Temporomandibular Disorder, Trigeminal Neuropathic Pain	20
11080299	4	2011	21508220	Increases in Patients	Gray Matter	Disease Effects	Temporomandibular Disorder, Trigeminal Neuropathic Pain	20
11080300	1	2007	17641373	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	10
11080301	1	2010	19817822	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	20
11080301	2	2010	19817822	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	20
11080302	1	2011	21296501	Increases in Controls	Gray Matter	Disease Effects	Chronic Pain, Normals	31
11080303	1	2011	20832482	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	15
11080303	2	2011	20832482	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	15
11080303	3	2011	20832482	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	15
11080303	4	2011	20832482	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	10
11080304	1	2007	17240166	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	9
11080304	2	2007	17240166	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	7
11080305	1	2011	21386751	Increases in Controls	Gray Matter	Disease Effects	Normals, Preterm Birth	22
11080305	2	2011	21386751	Neither	Gray Matter	Disease Effects	Preterm Birth	14
11080305	3	2011	21386751	Neither	Gray Matter	Disease Effects	Preterm Birth	12
11080305	5	2011	21386751	Increases in Controls	White Matter	Disease Effects	Normals, Preterm Birth	22
11080305	6	2011	21386751	Neither	White Matter	Disease Effects	Preterm Birth	14
11080305	7	2011	21386751	Neither	Gray Matter	Disease Effects	Preterm Birth	22
11080306	1	2011	21384430	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Normals, Parkinson's Disease	36
11080306	2	2011	21384430	Increases in Patients	Gray Matter	Disease Effects, Drug Effects	Normals, Parkinson's Disease	36
11080307	1	2011	21362743	Increases in Controls	Gray Matter	Disease Effects	22q11.2 Deletion Syndrome	29
11080307	2	2011	21362743	Increases in Controls	Gray Matter	Disease Effects	22q11.2 Deletion Syndrome	29
11080308	1	2011	21138758	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	23
11080308	2	2011	21138758	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	23
11080308	3	2011	21138758	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
11080308	4	2011	21138758	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
11080309	1	2004	15538599	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
11080309	2	2004	15538599	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	25
11080309	3	2004	15538599	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizotypal Personality Disorder	25
11080309	4	2004	15538599	Neither	Gray Matter	Disease Effects	Schizophrenia, Schizotypal Personality Disorder	25
11080311	1	2006	16951571	Neither	Gray Matter	Normal Mapping, Genotype Effects	Normals	23
11080311	2	2006	16951571	Neither	Gray Matter	Normal Mapping, Genotype Effects	Normals	23
11080312	1	2007	17240165	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
11080313	1	2011	21316203	Neither	Gray Matter	Normal Mapping	Normals	17
11080313	2	2011	21316203	Neither	Gray Matter	Normal Mapping	Normals	17
11080313	3	2011	21316203	Increases in Controls	Gray Matter	Disease Effects	Psychosis	14
11080313	4	2011	21316203	Increases in Patients	Gray Matter	Disease Effects	Normals, Psychosis	17
11080313	5	2011	21316203	Increases in Controls	Gray Matter	Disease Effects	Normals, Psychosis	17
12060001	1	2011	21146593	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	20
12060001	2	2011	21146593	Increases in Patients	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	20
12060001	3	2011	21146593	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	20
12060001	4	2011	21146593	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	7
12060001	5	2011	21146593	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	7
12060002	1	1999	10501551	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
12060002	2	1999	10501551	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
12060003	1	2012	21896334	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Idiopathic Developmental Delay, Normals	19
12060004	1	2011	21541322	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	25
12060004	2	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	25
12060004	3	2011	21541322	Neither	Gray Matter	Normal Mapping	Normals	25
12060004	4	2011	21541322	Neither	Gray Matter	Disease Effects	Autism Spectrum Disorder	25
12060004	5	2011	21541322	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	11
12060004	6	2011	21541322	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
12060004	7	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	11
12060004	8	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
12060004	9	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	11
12060004	10	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	11
12060004	11	2011	21541322	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	25
12060004	12	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	25
12060004	13	2011	21541322	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	11
12060004	14	2011	21541322	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
12060004	15	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	11
12060004	16	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	12
12060004	17	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	11
12060004	18	2011	21541322	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	11
12060004	19	2011	21541322	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	25
12060004	20	2011	21541322	Increases in Patients	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	25
12060004	21	2011	21541322	Neither	Gray Matter	Normal Mapping	Normals	25
12060004	22	2011	21541322	Neither	Gray Matter	Disease Effects	Autism Spectrum Disorder	25
12060005	1	2011	21531390	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	52
12060006	1	2002	12077008	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	17
12060006	2	2002	12077008	Increases in Controls	White Matter	Disease Effects	Asperger's Syndrome, Normals	17
12060006	3	2002	12077008	Increases in Patients	White Matter	Disease Effects	Asperger's Syndrome, Normals	17
12060007	1	2005	15548557	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	17
12060007	2	2005	15548557	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	17
12060008	1	2011	21700792	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	21
12060009	1	2007	17710821	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	9
12060009	2	2007	17710821	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	9
12060009	3	2007	17710821	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	9
12060009	4	2007	17710821	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	13
12060009	5	2007	17710821	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	9
12060009	6	2007	17710821	Neither	Gray Matter	Disease Effects	Autism Spectrum Disorder	9
12060010	1	2010	19891805	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	33
12060010	2	2010	19891805	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	33
12060010	3	2010	19891805	Increases in Controls	Gray Matter	Disease Effects	Asperger's Syndrome, Normals	33
12060010	4	2010	19891805	Increases in Controls	White Matter	Disease Effects	Asperger's Syndrome, Normals	33
12060010	5	2010	19891805	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	26
12060010	6	2010	19891805	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	26
12060010	7	2010	19891805	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	26
12060010	8	2010	19891805	Increases in Patients	Gray Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	26
12060010	9	2010	19891805	Increases in Patients	White Matter	Disease Effects	Asperger's Syndrome, Autism Spectrum Disorder	26
12060011	1	2004	15193590	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	16
12060012	1	2005	15627587	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	15
12070013	1	2008	18413913	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	10
12070013	2	2008	18413913	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	10
12070014	1	2007	16979268	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	10
12070014	2	2007	16979268	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	10
12070015	1	2008	17825801	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	18
12070016	1	2007	17852008	Increases in Controls	Gray Matter	Disease Effects, Genotype Effects	Hereditary Spastic Paraparesis, Normals	17
12070016	2	2007	17852008	Increases in Controls	Gray Matter	Disease Effects, Genotype Effects	Hereditary Spastic Paraparesis, Normals	12
12070016	3	2007	17852008	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Hereditary Spastic Paraparesis, Normals	17
12070016	4	2007	17852008	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Hereditary Spastic Paraparesis, Normals	12
12070017	1	2009	18981063	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	68
12070018	1	2007	17712410	Increases in Controls	Gray Matter	Normal Mapping	Normals	15
13060001	1	2011	21246668	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	21
13060001	2	2011	21246668	Increases in Patients	Gray Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	11
13060001	3	2011	21246668	Increases in Patients	Gray Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	11
13060001	4	2011	21246668	Increases in Patients	Gray Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	10
13060001	5	2011	21246668	Increases in Patients	Gray Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	10
13060001	6	2011	21246668	Increases in Patients	White Matter	Disease Effects	Normals, Parkinson's Disease	21
13060001	7	2011	21246668	Increases in Patients	White Matter	Disease Effects	Multiple-System Atrophy, Parkinson's Disease	11
13060001	8	2011	21246668	Increases in Patients	White Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	10
13060001	9	2011	21246668	Increases in Patients	White Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	10
13060001	10	2011	21246668	Increases in Patients	White Matter	Disease Effects	Multiple-System Atrophy, Progressive Supranuclear Palsy (PSP)	10
13100002	1	2009	null	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	25
13100002	2	2009	null	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	25
13100003	1	2011	21303677	Neither	Unknown		Stroke	7
13100004	1	2011	21546219	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	10
13100004	2	2011	21546219	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	10
13100004	3	2011	21546219	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	11
13100005	1	2007	17098213	Increases in Controls	Gray Matter	Disease Effects	At Risk for Psychosis, Normals	22
13100005	2	2007	17098213	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	12
13100005	3	2007	17098213	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	12
13100007	1	2011	22093442	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	6
13100007	2	2011	22093442	Increases in Patients	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	6
13100007	3	2011	22093442	Neither	Gray Matter	Disease Effects	Anorexia Nervosa	6
13100010	1	2009	19478293	Increases in Controls	White Matter	Disease Effects	Bipolar Disorder, Normals	18
13100011	1	2010	21058077	Neither	Gray Matter	Disease Effects	Brain Lesion	41
13100011	2	2010	21058077	Neither	Gray Matter	Disease Effects	Brain Lesion	41
13100011	3	2010	21058077	Neither	Gray Matter	Disease Effects	Brain Lesion	41
13100011	4	2010	21058077	Neither	White Matter	Disease Effects	Brain Lesion	41
13100011	5	2010	21058077	Neither	White Matter	Disease Effects	Brain Lesion	41
13100011	6	2010	21058077	Neither	White Matter	Disease Effects	Brain Lesion	41
13100014	1	2010	20594947	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	68
13100014	2	2010	20594947	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	68
13100015	1	2007	17008330	Neither	Unknown	Disease Effects	Stroke	6
13100015	2	2007	17008330	Neither	Unknown	Disease Effects	Stroke	6
13100016	1	2003	14625455	Neither	Unknown	Disease Effects	Stroke	11
13100016	2	2003	14625455	Neither	Unknown	Disease Effects	Stroke	10
13100016	3	2003	14625455	Neither	Unknown	Disease Effects	Stroke	10
13100016	4	2003	14625455	Neither	Unknown	Disease Effects	Stroke	10
13100016	5	2003	14625455	Neither	Unknown	Disease Effects	Stroke	10
13100016	6	2003	14625455	Neither	Unknown	Disease Effects	Stroke	10
13100017	1	2010	20184807	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	38
13100017	2	2010	20184807	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	38
13100017	3	2010	20184807	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	38
13100017	4	2010	20184807	Neither	Gray Matter	Disease Effects	Schizophrenia	38
13100018	1	2010	20678507	Neither	Unknown	Disease Effects	Stroke	68
13100019	1	2001	11335691	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
13100019	2	2001	11335691	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
13100019	3	2001	11335691	Neither	Gray Matter	Disease Effects	Schizophrenia	25
13100020	1	2012	21967727	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	12
13100020	2	2012	21967727	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	13
13100020	3	2012	21967727	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	13
13100020	4	2012	21967727	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa	12
13100021	1	2008	18838632	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	30
13100024	1	2011	21081268	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	16
13100025	1	2005	15721994	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	34
13100025	2	2005	15721994	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	34
13100026	1	2008	18808713	Neither	Unknown		Stroke	22
13100027	1	2008	18206963	Neither	Unknown	Disease Effects	Stroke	1
13100027	2	2008	18206963	Neither	Unknown	Disease Effects	Stroke	1
13100029	1	2010	20430976	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	26
13100029	2	2010	20430976	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	26
13100029	3	2010	20430976	Increases in Controls	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	26
13100029	4	2010	20430976	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	27
13100029	5	2010	20430976	Increases in Controls	White Matter	Disease Effects	Major Depressive Disorder (MDD)	27
13100030	1	2011	21406159	Increases in Controls	Gray Matter	Disease Effects	Huntington's Disease, Normals	18
13100031	1	2011	20977527	Increases in Controls	Gray Matter	Disease Effects	Anxiety, Major Depressive Disorder (MDD)	49
13100031	2	2011	20977527	Increases in Controls	Gray Matter	Disease Effects	Anxiety, Major Depressive Disorder (MDD), Normals	49
13100032	1	2004	15142954	Neither	Unknown		Stroke	62
13100032	2	2004	15142954	Neither	Unknown		Stroke	62
13100033	1	2003	12634499	Neither	Unknown	Disease Effects	Stroke	27
13100034	1	2010	19777553	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	49
13100034	2	2010	19777553	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	49
13100035	1	2007	17615169	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	6
13100035	2	2007	17615169	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	8
13100035	3	2007	17615169	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	6
13100036	1	2008	18356765	Neither	Gray Matter	Normal Mapping	Normals	20
13100036	2	2008	18356765	Neither	Gray Matter	Normal Mapping	Normals	20
13100037	1	2010	20599363	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	15
13100039	1	2010	19931620	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	25
13100039	2	2010	19931620	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	19
13100039	3	2010	19931620	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	19
13100039	4	2010	19931620	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	19
13100040	1	2009	19687454	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	10
13100040	2	2009	19687454	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	51
13100040	3	2009	19687454	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	11
13100040	4	2009	19687454	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	51
13100040	5	2009	19687454	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	51
13100040	6	2009	19687454	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	11
13100040	7	2009	19687454	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	11
13100040	8	2009	19687454	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	10
13100040	9	2009	19687454	Neither	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration	10
13100041	1	2005	15811244	Neither	Unknown	Disease Effects	Stroke	8
13100043	1	2007	17291727	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	10
13100043	2	2007	17291727	Increases in Controls	White Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	10
13100044	1	2005	15939409	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	26
13100044	2	2005	15939409	Increases in Controls	White Matter	Disease Effects	Bipolar Disorder, Normals	26
13100044	3	2005	15939409	Increases in Controls	White Matter	Disease Effects	Normals	26
13100045	1	2007	17014827	Increases in Patients	Gray Matter	Genotype Effects	At Risk for Psychosis, Normals	3
13100045	2	2007	17014827	Increases in Patients	Gray Matter	Genotype Effects	At Risk for Psychosis, Normals	3
13100046	1	2009	19016599	Neither	Unknown	Disease Effects	Stroke	171
13100046	2	2009	19016599	Neither	Unknown	Disease Effects	Stroke	171
13100047	1	2008	18367603	Neither	Unknown	Disease Effects	Stroke	20
13100048	1	2011	21829578	Neither	Unknown	Disease Effects	Normals	44
13100048	2	2011	21829578	Neither	Unknown	Disease Effects	Normals	44
13100049	1	2010	19854618	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	19
13100052	1	2007	17720459	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	28
13100052	2	2007	17720459	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	28
13100052	3	2007	17720459	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	28
13100052	4	2007	17720459	Increases in Patients	CSI	Disease Effects	Normals, Schizophrenia	28
13100053	1	2006	16330500	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	19
13100053	2	2006	16330500	Increases in Patients	CSI	Disease Effects	Normals, Schizophrenia	19
13100053	3	2006	16330500	Neither	Gray Matter	Genotype Effects, Disease Effects	Normals, Schizophrenia	19
13100053	4	2006	16330500	Neither	Gray Matter	Genotype Effects, Disease Effects	Normals, Schizophrenia	19
13100054	1	2001	11722157	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	16
13100054	2	2001	11722157	Increases in Controls	White Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	16
13100055	1	2011	20947646	Increases in Controls	Gray Matter	Disease Effects	Cervical Dystonia, Normals	19
13100056	1	2010	19632338	Increases in Controls	Gray Matter	Disease Effects	Normals, Psychosis	47
13100056	2	2010	19632338	Increases in Patients	Gray Matter	Disease Effects	Normals, Psychosis	47
13100056	3	2010	19632338	Increases in Controls	White Matter	Disease Effects	Normals, Psychosis	47
13100057	1	2006	16843641	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	12
13100058	1	2010	20861361	Neither	White Matter	Disease Effects	Stroke	9
13100059	1	2004	15237084	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	72
13100059	2	2004	15237084	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	72
13100059	3	2004	15237084	Increases in Patients	CSI	Disease Effects	Normals, Obsessive Compulsive Disorder	72
13100060	1	2011	21519374	Neither	Unknown	Disease Effects	Stroke	30
13100062	1	2011	21073959	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	58
13100062	2	2011	21073959	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	27
13100062	3	2011	21073959	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	27
13100062	4	2011	21073959	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	58
13100062	5	2011	21073959	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	27
13100062	6	2011	21073959	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	27
13100063	1	2010	20569645	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	13
13100063	2	2010	20569645	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	13
13100064	1	2012	21205677	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	27
13100064	2	2012	21205677	Neither	Gray Matter	Disease Effects	Schizophrenia	27
13100064	3	2012	21205677	Neither	Gray Matter	Disease Effects	Schizophrenia	27
13100065	1	2008	18268196	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	15
13100065	2	2008	18268196	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	15
13100065	3	2008	18268196	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	15
13100067	1	1998	9828995	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
13100067	2	1998	9828995	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
13100067	3	1998	9828995	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
13100067	4	1998	9828995	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
13100067	5	1998	9828995	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	20
13100068	1	2002	12427683	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	31
13100068	2	2002	12427683	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	31
13100068	3	2002	12427683	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	31
13100068	4	2002	12427683	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	32
13100068	5	2002	12427683	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	32
13100068	6	2002	12427683	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	32
13100068	7	2002	12427683	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	32
13100068	8	2002	12427683	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	31
13100068	9	2002	12427683	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	31
13100068	10	2002	12427683	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	31
13100068	11	2002	12427683	Neither	Gray Matter	Disease Effects	Schizophrenia	31
13100069	1	2011	20875637	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	40
13100069	2	2011	20875637	Increases in Patients	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	40
13100069	3	2011	20875637	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	70
13100069	4	2011	20875637	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	70
13100069	5	2011	20875637	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	30
13100069	6	2011	20875637	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	30
13100069	7	2011	20875637	Neither	White Matter	Disease Effects	Major Depressive Disorder (MDD)	30
13100069	8	2011	20875637	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	30
13100069	9	2011	20875637	Neither	White Matter	Disease Effects	Major Depressive Disorder (MDD)	70
13100070	1	2010	null	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	8
13100070	2	2010	null	Increases in Patients	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	8
13100070	3	2010	null	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	11
13100070	4	2010	null	Increases in Patients	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	11
13100071	1	2011	21310245	Increases in Patients	Gray Matter	Disease Effects	Essential Blepharospasm, Normals	32
13100071	2	2011	21310245	Neither	Gray Matter	Disease Effects	Essential Blepharospasm	32
13100071	3	2011	21310245	Neither	Gray Matter	Disease Effects	Essential Blepharospasm	32
13100072	1	2011	21113581	Increases in Controls	White Matter	Disease Effects	Normals, Stroke	6
13100072	2	2011	21113581	Increases in Controls	White Matter	Disease Effects	Normals, Stroke	6
13100072	3	2011	21113581	Increases in Controls	White Matter	Disease Effects	Normals, Stroke	6
13100072	4	2011	21113581	Increases in Controls	White Matter	Disease Effects	Normals, Stroke	6
13100072	5	2011	21113581	Increases in Controls	White Matter	Disease Effects	Stroke	6
13100073	1	2010	20921116	Increases in Controls	Gray Matter	Disease Effects	Anxiety, Major Depressive Disorder (MDD), Normals	65
13100073	2	2010	20921116	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	65
13100073	3	2010	20921116	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	65
13100073	4	2010	20921116	Increases in Controls	Gray Matter	Disease Effects	Anxiety, Normals	65
13100073	5	2010	20921116	Increases in Controls	White Matter	Disease Effects	Anxiety, Major Depressive Disorder (MDD), Normals	65
13100073	6	2010	20921116	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	65
13100073	7	2010	20921116	Other	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	68
13100073	8	2010	20921116	Other	Gray Matter	Disease Effects	Anxiety	68
13100074	1	2010	20028714	Neither	White Matter	Disease Effects	Stroke	16
13100074	2	2010	20028714	Neither	White Matter	Disease Effects	Stroke	16
13100074	3	2010	20028714	Neither	White Matter	Disease Effects	Stroke	80
13100074	4	2010	20028714	Neither	White Matter	Disease Effects	Stroke	80
13100074	5	2010	20028714	Neither	White Matter	Disease Effects	Stroke	80
13100075	1	2011	21242287	Neither	Unknown	Disease Effects	Stroke	56
13100075	2	2011	21242287	Neither	Unknown	Disease Effects	Stroke	56
13100075	3	2011	21242287	Neither	Unknown	Disease Effects	Stroke	56
13100075	4	2011	21242287	Neither	Unknown	Disease Effects	Stroke	56
13100076	1	2007	1735333	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	12
13100076	2	2007	1735333	Increases in Patients	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	12
13100077	1	2007	17606660	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	41
13100077	2	2007	17606660	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	41
13100077	3	2007	17606660	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	25
13100079	1	2009	19211150	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	15
13100079	2	2009	19211150	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	15
13100080	1	2011	21498053	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	10
13100081	1	2010	19897176	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	23
13100082	1	2007	17346990	Neither	Gray Matter	Genotype Effects	Normals	6
13100082	2	2007	17346990	Neither	Gray Matter	Genotype Effects	Normals	6
13100082	3	2007	17346990	Neither	White Matter	Genotype Effects	Normals	6
13100082	4	2007	17346990	Neither	White Matter	Genotype Effects	Normals	6
13100082	5	2007	17346990	Neither	Gray Matter	Genotype Effects	Normals	5
13100082	6	2007	17346990	Neither	Gray Matter	Genotype Effects	Normals	5
13100082	7	2007	17346990	Neither	White Matter	Genotype Effects	Normals	5
13100082	8	2007	17346990	Neither	White Matter	Genotype Effects	Normals	5
13100084	1	2010	20597976	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	10
13100084	2	2010	20597976	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	10
13100084	3	2010	20597976	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	10
13100084	4	2010	20597976	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	10
13100084	5	2010	20597976	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	10
13100085	1	2011	21177393	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment, Normals	15
13100085	2	2011	21177393	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
13100085	3	2011	21177393	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	15
13100085	4	2011	21177393	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	15
13100089	1	2011	21689852	Increases in Controls	Gray Matter	Disease Effects	Lewy Body Dementia, Normals	11
13100089	2	2011	21689852	Increases in Controls	Gray Matter	Disease Effects	Lewy Body Dementia	11
13100090	1	2009	22180700	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	6
13100090	2	2009	22180700	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	7
13100090	3	2009	22180700	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	9
13100090	4	2009	22180700	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals, Progressive Nonfluent Aphasia, Semantic Dementia	6
13100092	1	2005	15585344	Increases in Controls	Gray Matter	Disease Effects	Dementia, Normals	9
13100093	1	2010	20006324	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	28
13100093	2	2010	20006324	Increases in Controls	Gray Matter	Disease Effects, Genotype Effects	Normals, Schizophrenia	9
13100094	1	2009	19450953	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	33
13100096	1	2009	18573676	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	43
13100096	2	2009	18573676	Neither	Gray Matter	Disease Effects, Learning	Parkinson's Disease	43
13100096	3	2009	18573676	Neither	Gray Matter	Disease Effects	Parkinson's Disease	43
13100096	4	2009	18573676	Neither	Gray Matter	Disease Effects	Parkinson's Disease	43
13100096	5	2009	18573676	Neither	White Matter	Disease Effects	Parkinson's Disease	43
13100097	1	2011	21037021	Increases in Controls	Gray Matter	Disease Effects	Normals, Obstructive Sleep Apnea	15
13100097	2	2011	21037021	Increases in Controls	Gray Matter	Disease Effects	Obstructive Sleep Apnea	16
13100097	3	2011	21037021	Neither	Gray Matter	Disease Effects	Obstructive Sleep Apnea	16
13100098	1	2009	19349151	Increases in Patients	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	24
13100098	2	2009	19349151	Increases in Patients	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	24
13100099	1	2009	19172642	Increases in Controls	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	17
13100102	1	2012	22226599	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	16
13100103	1	2011	21461742	Neither	Gray Matter	Disease Effects	Ataxia, Normals	12
13100103	2	2011	21461742	Neither	Gray Matter	Disease Effects	Ataxia, Normals	12
13100103	3	2011	21461742	Neither	White Matter	Disease Effects	Ataxia, Normals	12
13100103	4	2011	21461742	Neither	Gray Matter	Disease Effects	Ataxia, Normals	12
13100103	5	2011	21461742	Neither	Gray Matter	Disease Effects	Ataxia	12
13100103	6	2011	21461742	Neither	Gray Matter	Disease Effects	Ataxia	12
13100105	1	2004	15033185	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	11
13100106	1	2011	21118656	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	13
13100107	1	2012	22310506	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	89
13100107	2	2012	22310506	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	89
13100107	3	2012	22310506	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	89
13100107	4	2012	22310506	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	89
13100107	5	2012	22310506	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	89
13100108	1	2010	19683584	Increases in Patients	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	22
13100108	2	2010	19683584	Increases in Controls	Gray Matter	Disease Effects	Autism Spectrum Disorder, Normals	22
13100108	3	2010	19683584	Increases in Patients	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	22
13100108	4	2010	19683584	Increases in Controls	White Matter	Disease Effects	Autism Spectrum Disorder, Normals	22
13100109	1	2001	11706094	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	8
13100110	1	2007	17399959	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	7
13100110	2	2007	17399959	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	7
13100110	3	2007	17399959	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	7
13100110	4	2007	17399959	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	7
13100114	1	2011	21600833	Neither	Gray Matter	Disease Effects, Genotype Effects	Ataxia, Normals	12
13100114	2	2011	21600833	Neither	Gray Matter	Disease Effects, Genotype Effects	Ataxia, Normals	9
13100114	3	2011	21600833	Neither	Gray Matter	Disease Effects, Genotype Effects	Ataxia, Normals	10
13100114	4	2011	21600833	Neither	Gray Matter	Disease Effects, Genotype Effects	Ataxia	9
13100114	5	2011	21600833	Neither	Gray Matter	Disease Effects, Genotype Effects	Ataxia	10
13100114	6	2011	21600833	Neither	White Matter	Disease Effects, Genotype Effects	Ataxia, Normals	12
13100114	7	2011	21600833	Neither	White Matter	Disease Effects	Ataxia, Normals	9
13100114	8	2011	21600833	Neither	White Matter	Disease Effects, Genotype Effects	Ataxia	9
13100114	9	2011	21600833	Neither	White Matter	Disease Effects, Genotype Effects	Ataxia	10
13100114	10	2011	21600833	Neither	White Matter	Disease Effects, Genotype Effects	Ataxia	9
13100117	2	2011	21705464	Increases in Patients	Gray Matter	Disease Effects	Musician's Hand Dystonia, Normals	11
13100117	3	2011	21705464	Increases in Controls	Gray Matter	Disease Effects	Musician's Hand Dystonia, Normals	11
13100117	5	2011	21705464	Neither	Gray Matter	Disease Effects	Musician's Hand Dystonia, Normals	11
13100119	1	2008	18308812	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	44
13100119	2	2008	18308812	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	44
13100119	3	2008	18308812	Neither	Gray Matter	Normal Mapping	Normals	44
13100119	4	2008	18308812	Neither	Gray Matter	Disease Effects	Bipolar Disorder	44
13100119	5	2008	18308812	Neither	Gray Matter	Normal Mapping	Normals	44
13100119	6	2008	18308812	Neither	Gray Matter	Disease Effects	Bipolar Disorder	44
13100121	1	2007	17360506	Increases in Controls	Gray Matter	Disease Effects	Dyslexia, Normals	19
13100124	1	2009	20011063	Increases in Controls	White Matter	Disease Effects	Normals, Parkinson's Disease	18
13100125	1	2009	19647777	Increases in Controls	Gray Matter	Disease Effects	Schizophrenia	32
13100125	2	2009	19647777	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
13100125	3	2009	19647777	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
13100125	4	2009	19647777	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	18
13100127	1	2011	21570296	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	33
13100127	2	2011	21570296	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	31
13100127	3	2011	21570296	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	20
13100127	4	2011	21570296	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	10
13100128	1	2001	11581113	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	25
13100128	2	2001	11581113	Increases in Patients	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	25
13100129	1	2011	21950985	Increases in Controls	Gray Matter	Disease Effects	Ataxia, Normals	19
13100129	2	2011	21950985	Neither	Gray Matter	Disease Effects	Ataxia	31
13100130	1	2010	20702071	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder	12
13100132	1	2012	22386047	Increases in Controls	Gray Matter	Disease Effects	Normals, Panic Disorder	21
13100133	1	2011	21546094	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	47
13100133	2	2011	21546094	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	47
13100135	1	2011	21236649	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
13100137	1	2012	22511729	Neither	Gray Matter	Disease Effects	Anorexia Nervosa	18
13100137	2	2012	22511729	Increases in Controls	Gray Matter	Disease Effects	Anorexia Nervosa, Normals	18
13100138	1	2011	21717508	Increases in Patients	Gray Matter	Disease Effects	Normals, Primary Blepharospasm	24
13100138	2	2011	21717508	Increases in Patients	Gray Matter	Disease Effects	Normals, Primary Blepharospasm	24
13100138	3	2011	21717508	Increases in Controls	Gray Matter	Disease Effects	Normals, Primary Blepharospasm	24
13100139	1	2010	20923432	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	16
13100140	1	2008	18191587	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	8
13100143	1	2008	18779427	Increases in Patients	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	21
13100143	2	2008	18779427	Increases in Patients	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	21
13100143	3	2008	18779427	Neither	Gray Matter	Disease Effects	Multiple Sclerosis	35
13100144	1	2011	21692882	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	18
13100144	2	2011	21692882	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	16
13100144	3	2011	21692882	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Mild Cognitive Impairment	16
13100145	1	2011	21188405	Neither	Gray Matter	Disease Effects	Bipolar Disorder, Schizophrenia	19
13100145	2	2011	21188405	Neither	Gray Matter	Disease Effects	Bipolar Disorder, Schizophrenia	19
13100145	3	2011	21188405	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	24
13100145	4	2011	21188405	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	24
13100145	5	2011	21188405	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	19
13100146	1	2010	20861295	Increases in Controls	Gray Matter	Disease Effects	Normals, Obstructive Sleep Apnea	25
13100146	2	2010	20861295	Increases in Controls	Gray Matter	Disease Effects	Normals, Obstructive Sleep Apnea	25
13100149	1	2008	18311829	Increases in Controls	Gray Matter	Disease Effects, Genotype Effects	Ataxia, Normals	20
13100149	2	2008	18311829	Increases in Controls	White Matter	Disease Effects, Genotype Effects	Ataxia, Normals	20
13100149	3	2008	18311829	Increases in Patients	CSI	Disease Effects, Genotype Effects	Ataxia, Normals	20
13100150	1	2011	21205693	Increases in Controls	Gray Matter	Disease Effects	Juvenile Myoclonic Epilepsy, Normals	28
13100150	2	2011	21205693	Increases in Controls	White Matter	Disease Effects	Juvenile Myoclonic Epilepsy, Normals	28
13100151	1	2011	21727234	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	23
13100154	1	2001	11378311	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
13100154	2	2001	11378311	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	20
13100154	3	2001	11378311	Neither	White Matter	Disease Effects	Schizophrenia	20
13100155	1	2011	21991357	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	29
13100155	2	2011	21991357	Neither	Gray Matter	Disease Effects	Schizophrenia	33
13100155	3	2011	21991357	Neither	Gray Matter	Disease Effects, Drug Effects	Schizophrenia	33
13100157	1	2011	21311576	Increases in Controls	Gray Matter	Disease Effects	Normals, Spinocerebellar Ataxia	16
13100157	2	2011	21311576	Increases in Controls	Gray Matter	Disease Effects	Spinocerebellar Ataxia	16
13100158	1	2012	22422807	Increases in Patients	White Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	2	2012	22422807	Neither	White Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	3	2012	22422807	Neither	White Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	4	2012	22422807	Neither	White Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	5	2012	22422807	Increases in Patients	White Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	6	2012	22422807	Neither	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	7	2012	22422807	Neither	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	8	2012	22422807	Neither	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	9	2012	22422807	Neither	Gray Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100158	10	2012	22422807	Increases in Patients	White Matter	Disease Effects	Multiple Sclerosis, Normals	78
13100159	1	2011	21095105	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	14
13100160	1	2010	20546170	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	10
13100160	2	2010	20546170	Increases in Controls	Gray Matter	Disease Effects	Attention Deficit/Hyperactivity Disorder, Normals	8
13100161	1	2010	20347816	Increases in Controls	Gray Matter	Disease Effects	Irritable Bowel Syndrome (IBS), Normals	49
13100161	2	2010	20347816	Increases in Patients	Gray Matter	Disease Effects	Irritable Bowel Syndrome (IBS), Normals	49
13100165	1	2001	11156806	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	27
13100165	2	2001	11156806	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	27
13100166	1	2011	21370255	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	23
13100166	2	2011	21370255	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	18
13100166	3	2011	21370255	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	18
13100168	1	2002	11955962	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	42
13100168	2	2002	11955962	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	42
13100168	3	2002	11955962	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	22
13100168	4	2002	11955962	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
13100168	5	2002	11955962	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	20
13100168	6	2002	11955962	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	42
13100168	7	2002	11955962	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	42
13100168	8	2002	11955962	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	22
13100168	9	2002	11955962	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	20
13100168	10	2002	11955962	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	20
13100171	1	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Lewy Body Dementia, Normals	40
13100171	2	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Lewy Body Dementia, Normals	40
13100171	3	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
13100171	4	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	40
13100171	5	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Lewy Body Dementia	43
13100171	6	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Lewy Body Dementia	43
13100171	7	2010	20634303	Increases in Controls	White Matter	Disease Effects	Lewy Body Dementia, Normals	40
13100171	8	2010	20634303	Increases in Controls	White Matter	Disease Effects	Lewy Body Dementia, Normals	40
13100171	9	2010	20634303	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Lewy Body Dementia	43
13100171	10	2010	20634303	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Normals	40
13100171	11	2010	20634303	Increases in Controls	White Matter	Disease Effects	Alzheimer's Disease, Lewy Body Dementia	43
13100172	1	2011	22187545	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	16
13100172	2	2011	22187545	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	16
13100172	3	2011	22187545	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	16
13100172	4	2011	22187545	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	16
13100172	5	2011	22187545	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	16
13100172	6	2011	22187545	Neither	White Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	16
13100173	1	2010	19015212	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	54
13100174	1	2012	21710131	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	25
13100175	1	2007	17635981	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	15
13100176	1	2010	20673548	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	28
13100176	2	2010	20673548	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	28
13100177	1	2011	22174900	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	30
13100177	2	2011	22174900	Neither	Gray Matter	Normal Mapping	Normals	29
13100178	1	2010	20833001	Increases in Controls	Gray Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	23
13100178	2	2010	20833001	Increases in Patients	White Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	23
13100178	3	2010	20833001	Increases in Patients	White Matter	Disease Effects	Normals, Obsessive Compulsive Disorder	23
13100179	1	2011	20888921	Increases in Controls	Gray Matter	Disease Effects	Normals, Sleep-Related Breathing Disorders	14
13100179	2	2011	20888921	Neither	Gray Matter	Disease Effects	Normals, Sleep-Related Breathing Disorders	14
13100182	1	2011	21666263	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	41
13100183	1	2012	22056751	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	25
13100183	2	2012	22056751	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	25
13100183	3	2012	22056751	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	25
13100183	4	2012	22056751	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	25
13100183	5	2012	22056751	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
13100183	6	2012	22056751	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	24
13100183	7	2012	22056751	Increases in Controls	White Matter	Disease Effects	Bipolar Disorder, Normals	24
13100185	1	2004	16908994	Increases in Patients	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	9
13100185	2	2004	16908994	Increases in Patients	Gray Matter	Disease Effects	Frontotemporal Lobar Degeneration, Normals	8
13100186	1	2009	19022856	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	5
13100187	1	2011	21726553	Neither	Gray Matter	Normal Mapping	Normals	3
13100187	2	2011	21726553	Neither	Gray Matter	Normal Mapping	Normals	13
13100189	1	2005	16253483	Increases in Controls	Gray Matter	Disease Effects	Alzheimer's Disease, Normals	10
13100189	2	2005	16253483	Neither	Gray Matter	Disease Effects	Alzheimer's Disease, Progressive Nonfluent Aphasia	5
13100189	3	2005	16253483	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Nonfluent Aphasia	5
13100189	4	2005	16253483	Increases in Patients	Gray Matter	Disease Effects	Alzheimer's Disease, Progressive Nonfluent Aphasia	5
13100190	1	2009	19303459	Increases in Controls	Gray Matter	Disease Effects	Epilepsy, Normals	16
13100190	2	2009	19303459	Increases in Patients	Gray Matter	Disease Effects	Epilepsy, Normals	16
13100190	3	2009	19303459	Neither	Gray Matter	Disease Effects	Epilepsy	16
13100190	4	2009	19303459	Neither	Gray Matter	Disease Effects	Epilepsy	16
13100190	5	2009	19303459	Increases in Controls	White Matter	Disease Effects	Epilepsy, Normals	16
13100190	6	2009	19303459	Neither	White Matter	Disease Effects	Epilepsy	16
13100191	1	2011	22017223	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	20
13100191	2	2011	22017223	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizoaffective Disorder	18
13100192	1	2011	21862438	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	22
13100192	2	2011	21862438	Neither	Gray Matter	Disease Effects	Parkinson's Disease	24
13100193	1	2012	22595621	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	15
13100193	2	2012	22595621	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	12
13100193	3	2012	22595621	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	12
13100193	4	2012	22595621	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13100193	5	2012	22595621	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13100193	6	2012	22595621	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13100193	7	2012	22595621	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13100193	8	2012	22595621	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13100193	9	2012	22595621	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13100195	1	2007	17594330	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	18
13100195	2	2007	17594330	Neither	Gray Matter	Disease Effects	Parkinson's Disease	18
13100195	3	2007	17594330	Increases in Patients	Gray Matter	Disease Effects	Normals, Parkinson's Disease	20
13100196	1	2013	23785322	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	10
13100196	2	2013	23785322	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	10
13100196	3	2013	23785322	Increases in Patients	Gray Matter	Disease Effects	Normals, Parkinson's Disease	10
13100196	4	2013	23785322	Increases in Patients	Gray Matter	Disease Effects	Normals, Parkinson's Disease	10
13100196	5	2013	23785322	Increases in Controls	Gray Matter	Disease Effects	Essential Tremor, Normals	10
13100196	6	2013	23785322	Increases in Controls	Gray Matter	Disease Effects	Essential Tremor, Normals	10
13100196	7	2013	23785322	Increases in Patients	Gray Matter	Disease Effects	Essential Tremor, Normals	10
13100196	8	2013	23785322	Increases in Patients	Gray Matter	Disease Effects	Essential Tremor, Normals	10
13100196	9	2013	23785322	Neither	Gray Matter	Disease Effects	Essential Tremor, Parkinson's Disease	10
13100196	10	2013	23785322	Neither	Gray Matter	Disease Effects	Essential Tremor, Parkinson's Disease	10
13100196	11	2013	23785322	Neither	Gray Matter	Disease Effects	Essential Tremor, Parkinson's Disease	10
13100196	12	2013	23785322	Neither	Gray Matter	Disease Effects	Essential Tremor, Parkinson's Disease	10
13100197	1	2010	20686125	Increases in Patients	White Matter	Disease Effects	Normals, Parkinson's Disease	16
13100197	2	2010	20686125	Increases in Patients	White Matter	Disease Effects	Parkinson's Disease	16
13100197	3	2010	20686125	Increases in Patients	Gray Matter	Disease Effects	Normals, Parkinson's Disease	24
13100197	4	2010	20686125	Increases in Patients	Gray Matter	Disease Effects	Normals, Parkinson's Disease	16
13100197	5	2010	20686125	Increases in Patients	Gray Matter	Disease Effects	Normals, Parkinson's Disease	16
13100199	1	2013	20922809	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	11
13100199	2	2013	20922809	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	13
13100199	3	2013	20922809	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	11
13100200	1	2012	22538070	Neither	Gray Matter	Disease Effects	Parkinson's Disease	12
13100200	2	2012	22538070	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	12
13110201	1	2012	22387096	Increases in Controls	Gray Matter	Disease Effects	Endometriosis, Normals	17
13110201	2	2012	22387096	Increases in Patients	Gray Matter	Disease Effects	Endometriosis, Normals	17
13110201	3	2012	22387096	Increases in Controls	Gray Matter	Disease Effects	Endometriosis, Normals	14
13110201	4	2012	22387096	Increases in Patients	Gray Matter	Disease Effects	Endometriosis, Normals	14
13110201	5	2012	22387096	Increases in Patients	Gray Matter	Disease Effects	Chronic Pelvic Pain, Normals	6
13110203	1	2006	16624566	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	12
13110203	2	2006	16624566	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	12
13110204	1	2006	16361944	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	21
13110205	1	2007	17428976	Increases in Controls	Gray Matter	Disease Effects	Fibromyalgia, Normals	10
13110206	1	2009	19794204	Increases in Controls	White Matter	Disease Effects, Age Effects	Normals, Schizophrenia	17
13110206	2	2009	19794204	Increases in Patients	White Matter	Disease Effects, Age Effects	Normals, Schizophrenia	17
13110206	3	2009	19794204	Neither	White Matter	Disease Effects, Age Effects	Schizophrenia	17
13110206	4	2009	19794204	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	17
13110206	5	2009	19794204	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	17
13110206	6	2009	19794204	Neither	White Matter	Disease Effects	Schizophrenia	17
13110207	1	2010	19619664	Increases in Patients	White Matter	Disease Effects	Normals, Psychosis	54
13110208	1	2009	1989986	Increases in Controls	Gray Matter	Disease Effects	Normals, Osteoarthritis	32
13110208	2	2009	1989986	Increases in Controls	Gray Matter	Disease Effects	Osteoarthritis	10
13110209	1	2005	15741480	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	10
13110210	1	2010	20452334	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	38
13110211	1	2011	21205362	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	68
13110211	2	2011	21205362	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	22
13110211	3	2011	21205362	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	46
13110211	4	2011	21205362	Neither	White Matter	Disease Effects	Schizophrenia	22
13110212	1	2013	23828835	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	25
13110212	2	2013	23828835	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	15
13110212	3	2013	23828835	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	15
13110212	4	2013	23828835	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13110212	5	2013	23828835	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13110212	6	2013	23828835	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13110212	7	2013	23828835	Neither	Gray Matter	Disease Effects	Parkinson's Disease	15
13110213	1	2013	23913130	Neither	Gray Matter	Disease Effects	Parkinson's Disease	28
13110213	2	2013	23913130	Neither	Gray Matter	Disease Effects	Normals, Parkinson's Disease	28
13110214	1	2012	21850388	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	9
13110214	2	2012	21850388	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	9
13110215	1	2012	22933812	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	46
13110215	2	2012	22933812	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	25
13110215	3	2012	22933812	Increases in Controls	Gray Matter	Disease Effects	Normals, Parkinson's Disease	25
13110216	1	2013	23474765	Increases in Patients	Gray Matter	Disease Effects	Parkinson's Disease	16
13110216	2	2013	23474765	Increases in Patients	Gray Matter	Disease Effects	Parkinson's Disease	16
13120217	1	2013	23433857	Increases in Controls	Gray Matter		Major Depressive Disorder (MDD)	20
13120217	2	2013	23433857	Increases in Controls	Gray Matter	Disease Effects, Genotype Effects	Major Depressive Disorder (MDD), Normals	12
13120218	1	2013	23620451	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	22
13120218	2	2013	23620451	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	22
13120218	3	2013	23620451	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	22
13120219	6	2013	23453566	Other	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	13
13120219	7	2013	23453566	Other	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	13
13120220	1	2011	21320250	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Normals	26
13120220	2	2011	21320250	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
13120220	3	2011	21320250	Increases in Patients	Gray Matter	Disease Effects	Bipolar Disorder, Major Depressive Disorder (MDD)	20
13120220	4	2011	21320250	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	3
13120221	1	2012	22537357	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	22
13120222	1	2012	22129771	Increases in Controls	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Normals	30
13120222	2	2012	22129771	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	32
13120222	3	2012	22129771	Increases in Controls	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Major Depressive Disorder (MDD)	30
13120222	4	2012	22129771	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	32
13120222	5	2012	22129771	Neither	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Major Depressive Disorder (MDD), Normals	30
13120222	6	2012	22129771	Neither	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Major Depressive Disorder (MDD), Normals	30
13120222	7	2012	22129771	Neither	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Major Depressive Disorder (MDD), Normals	30
13120222	8	2012	22129771	Neither	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Major Depressive Disorder (MDD), Normals	30
13120222	9	2012	22129771	Increases in Controls	Gray Matter	Disease Effects	Cognitively Vulnerable to Depression, Major Depressive Disorder (MDD), Normals	30
13120223	1	2013	24133286	Increases in Controls	Gray Matter	Disease Effects	Parkinson's Disease	24
14010001	1	2007	18055941	Increases in Patients	Gray Matter	Disease Effects	Normals, Psychosis	12
14010001	2	2007	18055941	Increases in Patients	Gray Matter	Disease Effects	Normals, Psychosis	12
14010001	3	2007	18055941	Increases in Controls	Gray Matter	Disease Effects	Normals, Psychosis	12
14010001	4	2007	18055941	Increases in Patients	Gray Matter	Disease Effects	Normals, Psychosis	12
14010001	5	2007	18055941	Increases in Controls	Gray Matter	Disease Effects	Normals, Psychosis	12
14010001	6	2007	18055941	Increases in Patients	Gray Matter	Disease Effects	Normals, Psychosis	12
14010001	7	2007	18055941	Neither	Gray Matter	Disease Effects	Psychosis	12
14010001	8	2007	18055941	Neither	Gray Matter	Disease Effects	Psychosis	12
14010002	1	2011	20580022	Increases in Controls	Gray Matter	Disease Effects	At Risk for Psychosis, Normals	15
14010003	1	2011	21129489	Increases in Controls	Gray Matter	Disease Effects	At Risk for Psychosis, Normals	39
14010003	2	2011	21129489	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	39
14010003	3	2011	21129489	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	39
14010003	4	2011	21129489	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	39
14010003	5	2011	21129489	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	39
14010003	6	2011	21129489	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	39
14010003	7	2011	21129489	Neither	Gray Matter	Disease Effects	At Risk for Psychosis	39
14010004	1	2006	16497519	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	22
14010004	2	2006	16497519	Increases in Patients	White Matter	Disease Effects	Normals, Schizophrenia	22
14010004	3	2006	16497519	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	22
14010005	1	2003	12559861	Neither	Gray Matter	Disease Effects	Psychiatric Disorder, Psychosis	23
14010005	2	2003	12559861	Neither	Gray Matter	Disease Effects	Psychosis	10
14010005	3	2003	12559861	Neither	Gray Matter	Disease Effects	Psychosis	10
14010005	4	2003	12559861	Neither	Gray Matter	Disease Effects	Psychiatric Disorder	11
14030006	1	2011	21271792	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	2	2011	21271792	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	3	2011	21271792	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	4	2011	21271792	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	5	2011	21271792	Increases in Patients	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	6	2011	21271792	Increases in Patients	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	7	2011	21271792	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	8	2011	21271792	Increases in Controls	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	9	2011	21271792	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	10	2011	21271792	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	11	2011	21271792	Increases in Controls	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	12	2011	21271792	Increases in Patients	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	13	2011	21271792	Increases in Patients	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS), Normals	17
14030006	14	2011	21271792	Neither	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	15	2011	21271792	Neither	Gray Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	16	2011	21271792	Neither	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	17	2011	21271792	Neither	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	18	2011	21271792	Neither	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	19	2011	21271792	Neither	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	20	2011	21271792	Neither	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14030006	21	2011	21271792	Neither	White Matter	Disease Effects	Amyotrophic Lateral Sclerosis (ALS)	17
14050007	1	2012	22637582	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	22
14050007	2	2012	22637582	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	22
14050007	3	2012	22637582	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	22
14050007	4	2012	22637582	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	22
14050007	5	2012	22637582	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	23
14050007	6	2012	22637582	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	23
14050007	7	2012	22637582	Neither	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	22
14050007	8	2012	22637582	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	23
14050007	9	2012	22637582	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	23
14050007	10	2012	22637582	Neither	White Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	23
14050007	11	2012	22637582	Neither	White Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	23
14050008	1	2013	23477861	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	15
14050008	2	2013	23477861	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	15
14050008	3	2013	23477861	Neither	Gray Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	15
14050008	4	2013	23477861	Neither	Gray Matter	Disease Effects	Parkinson's Disease, Progressive Supranuclear Palsy (PSP)	15
14050008	5	2013	23477861	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	15
14050008	6	2013	23477861	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	15
14050008	7	2013	23477861	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	15
14050008	8	2013	23477861	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	15
14050008	9	2013	23477861	Neither	Gray Matter	Disease Effects	Progressive Supranuclear Palsy (PSP)	15
14050009	1	2013	24278277	Increases in Controls	Gray Matter	Disease Effects	Frontotemporal Dementia, Normals	16
14050009	2	2013	24278277	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	18
14050009	3	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia, Progressive Supranuclear Palsy (PSP)	16
14050009	4	2013	24278277	Increases in Controls	White Matter	Disease Effects	Frontotemporal Dementia, Normals	16
14050009	5	2013	24278277	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	18
14050009	6	2013	24278277	Neither	White Matter	Disease Effects	Frontotemporal Dementia, Progressive Supranuclear Palsy (PSP)	16
14050009	7	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	16
14050009	8	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	16
14050009	9	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	16
14050009	10	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	16
14050009	11	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	16
14050009	12	2013	24278277	Neither	Gray Matter	Disease Effects	Frontotemporal Dementia	16
14050010	1	2013	23078273	Increases in Controls	Gray Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	16
14050010	2	2013	23078273	Increases in Controls	Gray Matter	Disease Effects	Normals, Primary Progressive Apraxia	16
14050010	3	2013	23078273	Increases in Controls	White Matter	Disease Effects	Normals, Progressive Supranuclear Palsy (PSP)	16
14050010	4	2013	23078273	Increases in Controls	White Matter	Disease Effects	Normals, Primary Progressive Apraxia	16
14050011	1	2013	23489395	Increases in Controls	Gray Matter	Disease Effects	Bipolar Disorder, Normals	20
14070012	1	2009	17604879	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	13
14070012	2	2009	17604879	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	6
14070012	3	2009	17604879	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	13
14070012	4	2009	17604879	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	6
14070012	5	2009	17604879	Increases in Controls	Gray Matter	Disease Effects	Normals, Semantic Dementia	6
14070013	1	2011	20884362	Neither	Gray Matter	Normal Mapping	Normals	10
14070014	1	2011	21191610	Increases in Controls	Gray Matter	Disease Effects	Normals, Schizophrenia	30
14070014	2	2011	21191610	Increases in Patients	Gray Matter	Disease Effects	Normals, Schizophrenia	30
14070014	3	2011	21191610	Increases in Controls	White Matter	Disease Effects	Normals, Schizophrenia	30
14070014	4	2011	21191610	Neither	Gray Matter	Disease Effects, Treatment Effects	Schizophrenia	10
14070014	5	2011	21191610	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	10
14070015	1	2009	19641900	Increases in Patients	Gray Matter	Treatment Effects, Disease Effects	Normals, Schizophrenia	10
14070015	2	2009	19641900	Increases in Controls	Gray Matter	Disease Effects, Treatment Effects	Normals, Schizophrenia	10
14070015	3	2009	19641900	Increases in Patients	Gray Matter	Disease Effects, Treatment Effects	Normals, Schizophrenia	10
14070015	4	2009	19641900	Increases in Controls	Gray Matter	Treatment Effects, Disease Effects	Normals, Schizophrenia	10
14070015	5	2009	19641900	Neither	Gray Matter	Disease Effects, Treatment Effects	Schizophrenia	10
14070015	6	2009	19641900	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	10
14080016	1	2007	17906243	Neither	Gray Matter	Disease Effects, Treatment Effects	Schizophrenia	16
14080016	2	2007	17906243	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	16
14080016	3	2007	17906243	Increases in Controls	Gray Matter	Treatment Effects, Disease Effects	Normals, Schizophrenia	16
14080016	4	2007	17906243	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	16
14080016	5	2007	17906243	Increases in Patients	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	16
14080016	6	2007	17906243	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	16
14080016	7	2007	17906243	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	16
14080016	8	2007	17906243	Neither	Gray Matter	Treatment Effects, Disease Effects	Schizophrenia	16
14080016	9	2007	17906243	Neither	Gray Matter	Disease Effects, Treatment Effects	Schizophrenia	16
14080017	1	2005	15955500	Neither	Gray Matter	Age Effects, Normal Mapping	Normals	331
14080019	1	2009	19224210	Increases in Controls	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	19
14080020	1	2011	21071182	Neither	Gray Matter	Normal Mapping, Treatment Effects	Normals	16
14080021	1	2003	12805116	Neither	Gray Matter	Normal Mapping, Age Effects	Normals	12
14080022	1	2011	20607753	Neither	Gray Matter	Normal Mapping, Gender Effects, Age Effects	Normals	116
14080022	2	2011	20607753	Neither	Gray Matter	Age Effects, Gender Effects, Normal Mapping	Normals	111
14080022	3	2011	20607753	Neither	Gray Matter	Age Effects, Gender Effects, Normal Mapping	Normals	55
14080022	4	2011	20607753	Neither	Gray Matter	Age Effects, Gender Effects, Normal Mapping	Normals	55
14080022	5	2011	20607753	Neither	Gray Matter	Age Effects, Gender Effects, Normal Mapping	Normals	35
14080022	6	2011	20607753	Neither	Gray Matter	Age Effects, Gender Effects, Normal Mapping	Normals	35
14080024	1	2007	17683950	Increases in Patients	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	22
14080024	2	2007	17683950	Increases in Patients	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	22
14080024	3	2007	17683950	Increases in Patients	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	13
14080024	4	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	13
14080024	5	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	13
14080024	6	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	22
14080024	7	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	22
14080024	8	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	13
14080024	9	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	13
14080024	10	2007	17683950	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	13
14080025	1	2008	18987469	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment, Normals	7
14080025	2	2008	18987469	Neither	Gray Matter	Disease Effects	Mild Cognitive Impairment	7
14090026	1	2013	22689216	Neither	Gray Matter	Normal Mapping	Normals	16
14110027	1	2012	22948482	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	21
14110028	1	2012	22453299	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	20
14110028	2	2012	22453299	Increases in Controls	Gray Matter	Disease Effects	Normals	14
14110028	3	2012	22453299	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110028	4	2012	22453299	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	20
14110028	5	2012	22453299	Neither	Gray Matter	Disease Effects	Normals	14
14110029	1	2012	23155380	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	10
14110029	2	2012	23155380	Increases in Controls	Gray Matter	Normal Mapping	Normals	10
14110029	3	2012	23155380	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	10
14110029	4	2012	23155380	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	10
14110030	1	2012	22720021	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	10
14110031	1	2012	22952599	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	16
14110032	1	2013	23746489	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	15
14110032	2	2013	23746489	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	15
14110033	1	2012	23021615	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	13
14110033	3	2012	23021615	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	13
14110034	1	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	2	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	3	2011	21592738	Neither	Gray Matter	Disease Effects, Age Effects	Post-Traumatic Stress Disorder	28
14110034	4	2011	21592738	Neither	Gray Matter	Disease Effects, Age Effects	Post-Traumatic Stress Disorder	28
14110034	5	2011	21592738	Neither	Gray Matter	Disease Effects, Gender Effects	Post-Traumatic Stress Disorder	28
14110034	6	2011	21592738	Neither	Gray Matter	Disease Effects, Gender Effects	Post-Traumatic Stress Disorder	28
14110034	7	2011	21592738	Neither	Unknown	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	8	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	9	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	10	2011	21592738	Neither	Gray Matter	Disease Effects, Age Effects	Post-Traumatic Stress Disorder	28
14110034	11	2011	21592738	Neither	Gray Matter	Disease Effects, Age Effects	Post-Traumatic Stress Disorder	28
14110034	12	2011	21592738	Neither	Gray Matter	Disease Effects, Gender Effects	Post-Traumatic Stress Disorder	28
14110034	13	2011	21592738	Neither	Gray Matter	Disease Effects, Gender Effects	Post-Traumatic Stress Disorder	28
14110034	14	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	15	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	16	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	17	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	18	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	19	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110034	20	2011	21592738	Neither	Gray Matter	Disease Effects	Post-Traumatic Stress Disorder	28
14110035	1	2013	23113800	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	2	2013	23113800	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	3	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	4	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	5	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	6	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	7	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	8	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	9	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	10	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110035	11	2013	23113800	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	15
14110036	1	2012	22453299	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	20
14110036	2	2012	22453299	Increases in Controls	Gray Matter	Disease Effects	Normals	14
14110036	3	2012	22453299	Increases in Controls	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	20
14110036	4	2012	22453299	Neither	Gray Matter	Disease Effects	Normals, Post-Traumatic Stress Disorder	20
14110036	5	2012	22453299	Neither	Gray Matter	Disease Effects	Normals	14
14120037	1	2013	23128153	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	39
14120037	2	2013	23128153	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	25
14120037	4	2013	23128153	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	15
14120037	5	2013	23128153	Neither	Gray Matter	Treatment Effects	Major Depressive Disorder (MDD)	25
14120037	6	2013	23128153	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	36
14120038	1	2014	23900024	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	2	2014	23900024	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	3	2014	23900024	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	4	2014	23900024	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	5	2014	23900024	Neither	Gray Matter	Normal Mapping	Normals	10
14120038	6	2014	23900024	Neither	Gray Matter	Normal Mapping	Normals	10
14120038	7	2014	23900024	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	8	2014	23900024	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	17
14120038	9	2014	23900024	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	17
14120038	10	2014	23900024	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	17
14120038	11	2014	23900024	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	12	2014	23900024	Neither	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	13	2014	23900024	Neither	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	14	2014	23900024	Increases in Patients	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	15	2014	23900024	Neither	White Matter	Normal Mapping	Normals	10
14120038	16	2014	23900024	Increases in Patients	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	17
14120038	17	2014	23900024	Neither	White Matter	Disease Effects	Major Depressive Disorder (MDD)	17
14120038	18	2014	23900024	Increases in Patients	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120038	19	2014	23900024	Increases in Controls	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	10
14120039	1	2013	24273717	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	34
14120039	2	2013	24273717	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	34
14120039	3	2013	24273717	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	34
14120040	1	2014	24210630	Increases in Controls	White Matter	Disease Effects	Major Depressive Disorder (MDD)	20
14120041	1	2013	23313294	Other	Gray Matter	Disease Effects	Depression, Panic Disorder	17
14120041	2	2013	23313294	Other	Gray Matter	Disease Effects	Depression	17
14120041	3	2013	23313294	Other	Gray Matter	Disease Effects	Depression	17
14120041	4	2013	23313294	Other	Gray Matter	Disease Effects	Depression, Panic Disorder	17
14120042	1	2014	24406440	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	19
14120042	2	2014	24406440	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	19
14120043	1	2013	23452374	Increases in Controls	White Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	25
14120044	1	2013	23831354	Increases in Controls	White Matter	Disease Effects	Depression, Normals	19
14120044	2	2013	23831354	Increases in Controls	White Matter	Disease Effects	Depression, Normals	19
14120044	3	2013	23831354	Other	White Matter	Disease Effects	Depression	19
14120044	4	2013	23831354	Neither	White Matter	Disease Effects	Depression, Normals	19
14120045	1	2014	25051163	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	132
14120045	2	2014	25051163	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	97
14120045	3	2014	25051163	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD)	132
14120046	1	2013	24099630	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	28
14120046	2	2013	24099630	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	21
14120046	3	2013	24099630	Neither	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	21
14120047	1	2013	24176247	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
14120048	1	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120048	2	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120048	3	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120048	4	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120048	5	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120048	6	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120048	7	2014	25066703	Neither	Gray Matter	Normal Mapping	Depression	54
14120049	1	2013	23929204	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
14120049	2	2013	23929204	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	20
14120050	1	2014	24863419	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	44
14120050	2	2014	24863419	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	24
14120050	3	2014	24863419	Increases in Controls	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	21
14120051	1	2014	24713859	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	46
14120051	2	2014	24713859	Increases in Patients	Gray Matter	Disease Effects	Major Depressive Disorder (MDD), Normals	46
14120052	1	2014	25003028	Neither	Gray Matter	Normal Mapping	Depression, Normals	63
14120052	2	2014	25003028	Neither	Gray Matter	Normal Mapping	Depression, Normals	63
14120052	3	2014	25003028	Neither	Gray Matter	Normal Mapping	Depression, Normals	63
14120053	1	2013	23090212	Increases in Patients	Gray Matter	Disease Effects	Friedreich Ataxia, Normals	22
14120053	2	2013	23090212	Increases in Patients	White Matter	Disease Effects	Friedreich Ataxia, Normals	22
14120053	3	2013	23090212	Other	Gray Matter	Disease Effects	Depression	8
14120053	4	2013	23090212	Other	Gray Matter	Disease Effects	Depression	8
14120054	1	2014	25218414	Increases in Controls	Gray Matter	Disease Effects	Depression, Normals	27
14120054	2	2014	25218414	Increases in Patients	Gray Matter	Disease Effects	Depression, Normals	27
14120054	3	2014	25218414	Other	Gray Matter	Disease Effects	Depression, Normals	27
